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Abstract 
 Protein biomarkers are valuable indicators of human physiological states. In clinical 
practice, they play a strong role in presymptomatic diagnosis of various diseases, as well as 
evaluation of disease prognosis and aid in treatment decisions making. Due to the importance of 
biomarkers, much efforts were made towards the discovery of good biomarker candidates, 
analytical methodologies for biomarker detection and quantitation, and ultimately, translation of 
the developed analytical platform to detect novel biomarkers in clinical practice.  
This dissertation places stronger emphasis on the latter two aspects of protein biomarker 
research: detection of biomarkers through immunoassays development, and translation of 
optimized assays to clinical samples analysis. For the immunoassays development aspect, assays 
described in this thesis were developed on a platform based on silicon photonic microring 
resonator technology. This sensing technology has high potential for clinical diagnostics utility, as 
sensor chips of this platform can be cheaply manufactured through a highly scalable process. 
Moreover, continuous improvements in sensor chip designs allowed rapid increase of biomarkers 
that can be detected simultaneously in a multiplexed panel. Multiplexed measurements are 
desirable due to the heterogeneity of the human population, and in many instances quantitation of 
multiple biomarkers are necessary to identify the disease state.  Additionally, the latest generation 
sensing platforms have integrated fluidic systems that can be programmed for immunoassay 
automation, which shortens intensive training required for clinical laboratory personnel to perform 
assay runs.  
For the translational aspect of applying novel biomarker detection to the clinical laboratory, 
collaborations have been established with hospital physicians for access to clinical samples from 
diseased patients. Blood serum or plasma samples from these patients have been evaluated by the 
immunoassays developed on the microring resonator platform, and results from the platform’s 
measurements are then evaluated against other established immunoassay techniques to assess 
assay performance. Translational research in clinical diagnostics is a trial and error process. Good 
immunoassays developed for novel biomarkers might not have good diagnostics value once placed 
into clinical evaluations, and thus the biomarker discovery and assay development research phases 
repeats through again. 
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This doctoral dissertation describes the progress of immunoassay development throughout 
the continuous improvements in the microring resonator platform, and eventually translates some 
of the developed assays to clinical samples analysis. Chapter 1 contains an introduction to protein 
biomarker immunoassays and their translational research value, with a more in depth description 
of microring resonators operation principles and the progression of the sensing platform 
development. Chapter 2 describes a simple detection of ricin toxin to illustrate the utility of 
microring resonators for protein analysis. Chapter 3 focuses on the development of an 8-plex panel 
to detect cancer biomarker that utilizes a protein multilayer strategy to improve assay signals. 
Chapter 4 explores the clinical utility of the platform by detecting monocyte chemactic protein-1 
in human serum matrix. Chapter 5 describes the detection and quantitation of cardiac troponin I in 
serum samples from cardiac disease patients. Chapter 6 demonstrates the development of a 
multiplexed assay panel to detect 12 immunoregulatory markers associated with sepsis, as well as 
application of the panel to test plasma samples from septic patients at the intensive care unit of a 
local hospital. Finally, Chapter 7 outlines the future work related to the cardiac troponins project 
and the sepsis project described in the previous two chapters. 
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Chapter 1: 
Introduction to Microring Resonators for 
Multiplexed Diagnostics 
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1.1 Protein biomarkers immunoassays 
Starting with the invention of an radioimmunoassay against blood insulin by Berson and 
Yalow in the 1950s,(1) protein biomarkers have played an increasingly important role in clinical 
diagnostics due to their predictive value in identifying disease types and progression. In protein 
biomarkers immunoassays, antibodies are utilized to detect low quantities of the target analyte 
biomarker in a sample of interest. These antibodies can be generated with high affinity and 
outstanding specificity against a wide range of biomolecules (known as antigens), which is crucial 
to the success of immunoassays.(2)  
Immunoassays can be classified as limited reagent and excess reagents formats.(3) Assays 
in limited reagent format are known as competitive binding assays, where a limited amount of 
antibodies is immobilized on a solid phase, typically a microwell plate. Subsequently, a mixture is 
introduced to compete for the limited binding sites of the immobilized antibodies; the mixture 
consists of the sample containing the analyte of interest, and a fix amount of antigen labeled with 
a signal molecule. As the analyte concentration in the sample increases, less of the labeled antigen 
can bind to the antibodies, resulting in a decrease of measured signal.  Thus, in a competitive 
binding assay, the analyte concentration is inversely related to the generated signal in a calibration 
curve.  
Assays in excess reagent format are known as sandwich immunoassays. Similar to 
competitive binding assays, capture antibodies are immobilized on a solid phase, and the sample 
containing the analyte is allowed to incubate and bind to the capture antibodies. Afterwards, excess 
amounts of tracer antibodies labeled with signal molecules are added. Both the capture and tracer 
antibodies can specifically bind to two different non-interfering epitopes of the analyte molecule, 
effectively forming a “sandwich”. In this type of assay, the analyte concentration is proportional 
to the generated signal.  
As mentioned earlier, the very first type of immunoassays utilized radioactive labels, but 
later they were modified to using enzyme labels that catalyze conversion of substrates to 
colorimetric signals.(4) This type of assay signaling format, known as enzyme-linked 
immunosorbent assays (ELISAs), turned out to be the most commonly adopted assay configuration. 
While this method is considered a gold standard for immunoassays, its main drawbacks for clinical 
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utility are in the large patients’ sample volume required, the laborious assay rinse steps, and the 
long incubation time to acquiring test results.(5) Moreover, traditionally ELISAs are used to target 
single biomarker analyte per sample, but a diagnosis based on detection of one single biomarker 
is often unreliable due to the inherent complexity of different diseases, and often multiple 
biomarker analysis is required.(6-8)  
In the 1980s, Roger Ekins first conceived the idea of multi-analyte immunoassays, which 
are built upon traditional immunoassay principles of utilizing multiple high affinity capture/tracer 
agents to detect biomarkers of interest.(9) More importantly, he proposed that miniaturization of 
immunoassay systems can improve sensitivity and selectivity due to shortening the diffusion 
distances, thus overcoming drawbacks of traditional ELISAs. This miniaturization theory also 
revolutionized clinical diagnostics, as it enables biomarker analysis from small volumes of clinical 
samples.(10) In the current era of personalized medicine, multiplexed biomarker immunoassays 
become essential for differentiating between individual patient’s characteristics among various 
disease states. This is because for many complex diseases such as inflammatory diseases and 
cancers, the underlying cell-signaling pathway induced by the disease is different even if patients 
are exhibiting similar physiological symptoms, and monitoring changes in multiple biomarkers 
involved in this intricate cell-signaling network is crucial to make an informative diagnosis and 
treatment decisions.(11, 12) 
1.2 Contemporary multiplexed biomarker immunoassays 
According to Tighe et al.,(13) current multiplexed biomarker immunoassays are generally 
categorized into two types: planar-based assays or suspension-based assays. As its name implies, 
planar-based assays consist of a planar surface immobilized with multiple capture agents to target 
biomarker analytes in the sample flowing across the surface. Fluorescent or chemiluminescent-
tagged tracer molecules targeting the captured analytes are commonly used as the reporter 
signal.(14) The classic example of this assay type are microarrays on glass slides, though there are 
other assays utilizing detection strategies outside of fluorescent or chemiluminescent labels, for 
example surface plasmon resonance (SPR), quartz crystal microbalance, or electrochemical 
sensing methodologies can also be classified as planar-based assays if a planar geometry is 
adopted.(15-19) In suspension-based assays, rather than utilizing a planar surface for immunoassay 
platform, unique fluorescent/chemiluminscent-coded beads conjugated with capture agents are 
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suspended into the sample to capture biomarker analytes. After incubation and rinsing steps, tracer 
molecules with fluorescent/chemiluminescent tags dissimilar to the ones used by the beads are 
added in to detect the analyte bound on the beads surface. Each of these beads can then be uniquely 
identified by flow cytometry principles.(20) A common example for suspension-based assays is 
the Luminex® system. 
Both the planar and suspension-based assay platforms have their advantages and 
limitations. Suspension-based assays have better precision due to their capabilities to have a large 
number of beads (50-100) for replicate measurements,(21) while precision of planar assays are 
limited by the spot density of capture agents on the planar platform. In terms of inter-assay 
precision, suspension assays have manufacturing variations of beads size, which can account for 
up to 32% difference in fluorescent readings,(22) whereas for planar assays the variability depends 
on the reproducibility of array spots from different automated printing techniques.(23) Both 
systems have cross-reactivity issues that arise from multiplexing, but suspension assays potentially 
have higher cross-reactivity due to the circulation of beads in sample that can freely interact with 
protein components and cross-link with one another.(13) For clinical applications, the capacity to 
automate the system is critical as well. In this regard, suspension assays are well integrated with 
automated flow cytometry techniques, while planar arrays are simpler to integrate microfluidics 
automation. Integration with microfluidics adds potential for manufacturing smaller, point-of-care 
devices that is important for translation of clinical diagnostics from bench to bedside. 
1.3 Introduction to microring resonators operation principles 
 Since this dissertation is centered on microring resonator sensors, it is important to describe 
the background theory of this technology and its operation principles. Microring resonators belong 
to a class of sensors known as whispering gallery mode (WGM) sensors. This terminology came 
from the phenomenon first observed by Lord Rayleigh at the dome of St. Paul’s Cathedral in 
London. He noticed that whispers from one end of the dome were audible at specific positions 
around the structure, and later on discovered that this phenomenon is due to resonance based on 
acoustic wave interference throughout the dome. Eventually, it was revealed that electromagnetic 
waves also exhibit similar resonance qualities, and many WGM optical sensors of various 
geometries were developed, as discussed in the comprehensive review by Vollmer and Arnold.(24) 
In the case of microring resonators, the geometry of the sensor is in a ring format. These structures 
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are fabricated via photolithographic patterning and reactive ion etching of features on silicon-on-
insulator (SOI) wafers. These features consist of 30-µm diameter circular waveguides etched 
adjacent to linear waveguides (200 nm × 500 nm cross section dimensions), with grating couplers 
at either end. Light from a tunable diode laser centered at 1550 nm is directed to the linear 
waveguides via the grating couplers, and couple to the microring structures upon optical resonance 
conditions governed by the following equation: 
݉ߣ ൌ 2ߨݎ݊௘௙௙ 
where ݉ is an integer, ߣ is the wavelength of light, ݎ is the radius of the microring, and ݊௘௙௙ is the 
effective refractive index of the optical mode. From the equation, it is apparent that the wavelength 
is sensitive to changes in refractive index at near proximity to the microring. Thus, any molecular 
binding events near the microring surface, for example antibodies immobilization on microrings 
and subsequent antibody-analyte interactions for assays described in this thesis, can alter the local 
refractive index and correspondingly cause a shift in resonance wavelength, which is monitored 
from the output light intensity in real time, as illustrated in Figure 1.1.(25, 26) 
1.4 Progression of the microring resonator platform development 
 The microring resonator chip arrays and instrumentation used in this thesis work were 
developed in collaboration with Genalyte, Inc. (San Diego, CA), and have undergone many 
iterations since the beginning of the dissertation. The first generation design was described in 
comprehensive detail by Iqbal,(25) and later design generations were built upon this work. Some 
key points to note for this first generation system is that the sensor chip array consists of 32 
individually addressable microrings on a 6 mm × 6 mm chip size, and the entire chip is spin coated 
with a perfluoropolymer cladding. Annular openings are etched off for 24 of the microrings, 
allowing them to actively interact with assay solutions to monitor binding interactions. The 
remaining 8 microrings are left covered by the perfluoropolymer and only respond to temperature 
fluctuations, effectively serving as thermal controls rings. To run an immunoassay experiment, a 
sensor chip immobilized with capture antibodies on the microrings is assembled in a cartridge 
consisting of an aluminum chip holder, a Mylar gasket that has fluidic cut-outs that direct solution 
flow over the microrings, and a Teflon piece with screwed in ports linking inlet fluidic tubings to 
assay reagents and the waste outlet to external syringe pumps. This first generation instrument was 
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used to perform ricin detection experiments described in Chapter 2. In the second generation 
design, named as Maverick M1 system, peristaltic fluidic pumps and an assay reagent holder stage 
were integrated into the instrument, and these components can be controlled by a connected 
computer uploaded with a pre-programed immunoassay recipe. This design greatly improved 
fluidic automation for assay runs. The sensor chip performance for the Maverick M1 system also 
greatly improved as well. In the initial “beta testing” design, the chip dimensions were altered 
down to 4 mm × 6 mm, while the number of microrings increased to 34 sensors, with 2 rings kept 
covered by the perfluoropolymer as thermal controls. This instrument version was used for the 
work of developing the 8-plex cancer biomarker panel described in Chapter 3. In the later version 
of the instrument, the number of microrings on each sensor chip further increased to 132 total rings, 
4 rings serving as thermal controls and the remaining 128 active sensor rings were grouped into 
32 clusters of 4 rings, which enables 4 replicate measurements for each cluster. This later 
instrument version was used for experiments described in Chapters 4 and 5. The latest generation 
instrument of the instrument is the Maverick M24 system. The sensor chips used in this system 
are identical to the 132-microrings sensors used in the later M1 design, but rather than manually 
assembling an individual chip to a cartridge prior to each experiment, these chips come pre-
assembled in a cartridge of 12 chips array, with the inlet/outlet ports and microfluidic channels 
integrated within the rack. This new set-up enables performing 12 consecutive experiments 
without interruptions, which greatly shortens preparation time and facilitates clinical samples 
testing for experiments described in Chapter 6 for sepsis diagnostics applications. 
1.5 Objective of thesis: Translation of microring resonator assays to clinical 
diagnostics 
The underlying theme of this dissertation is to translate protein immunoassays developed 
on the microring resonator platform to clinical diagnostics applications. As described by multiple 
literature sources, translational science is a cyclic process involving interconnection of four 
different research phases illustrated in Figure 1.2: discovery, development, delivery, and 
outcome.(3, 27-29) For the case of translating biomarkers immunoassays to clinical diagnostics, 
the discovery phase is the identification of novel biomarkers relevant to disease diagnosis, the 
development phase involves biomarker immunoassay development and validation on a clinical 
platform, the delivery phase is to apply the developed platform to evaluate clinical samples, and 
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finally the outcome phase involves interpretation of clinical results and assessment of public health 
outcomes upon implementing a new assay. Predictive analytics, a statistical method that utilizes a 
large volume of health data set to predict individual patient’s outcome, is often utilized to interpret 
clinical results.(30, 31) As shown in the diagram in Figure 1.2, these four research phases often 
interact with one another in no particular order. 
This dissertation mainly focuses on the development and delivery phases in translational 
research. For the development phase, our group has repeatedly demonstrated detection of various 
clinical protein biomarkers on microring resonator sensor platforms in the past,(26, 32-36) and this 
thesis work added upon that by optimizing assays for additional markers and expanding the 
number of biomarkers detectable on a multiplexed panel. The motivation behind utilizing this 
sensor platform comes from the many superior qualities over other multiplexed immunoassay 
platforms. Firstly, microring resonator arrays have well-established fabrication process through 
standard semiconductor processing technologies that enables mass-production of many devices in 
bulk for clinical use. Secondly, unlike immunoassays that are solely based on 
fluorescent/colorimetric endpoint signals, microring resonators can monitor each individual 
binding step of the assay in real-time, beginning from analyte binding to capture agents, tracer 
molecules binding to analyte, to later stages of incorporating amplification strategies. As selection 
of sensitive and selective capture agents play a highly important role to develop a sensitive 
immunoassay, this real-time monitoring of molecular interactions is highly useful in the initial 
stages of assay development, where multiple capture agents can be evaluated on their binding 
affinity to the analyte of interest, as well as their potential cross-reactivity to other assay 
components. 
Regarding the delivery phase focus in translational research, the work described in this 
thesis initiated the next step of translating protein biomarker assays to actual clinical utility. This 
was aided by the collaboration with clinicians and physicians from multiple hospitals, who were 
able to provide valuable patients’ samples to evaluate and optimize the performance of microring 
arrays immunoassays. The work developed in this dissertation has focused on developing 
immunoassays that have the ability to monitor disease onset, predict prognosis and treatment 
efficacy. This is also the fundamental goal of integrating analytical chemistry with translational 
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medicine, which aims to improve human health through translating findings from clinical 
diagnostic tools and implementing them to real-world practice. 
1.6 Outline of thesis 
 The chapters of this thesis document the concurrent innovation in assay design through 
the progressive improvements in the microring resonator platform setup. Chapter 2 describes the 
initial work of protein detection on microring resonators, using ricin toxin as a model. This chapter 
illustrates that different antibodies against the same molecular target can have dissimilar binding 
affinities, and microring resonators have the multiplexed capabilities to evaluate optimal 
antibodies for immunoassay development. Chapter 3 demonstrates multiplexed detection of cancer 
biomarkers in a complex human serum matrix, and also documents the use of protein multilayers 
to amplify signals for sandwich immunoassays. Chapter 4 focuses on the validation of clinical 
utility of the microring resonator platform through the detection and quantitation of clinically 
relevant concentration of monocyte chemotactic protein-1 in serum. Chapter 5 describes the 
detection and quantitation of cardiac troponin I in cardiac disease patients’ serum samples. Chapter 
6 illustrates the development of a 14-plex biomarker panel to monitor the fluctuation of 
immunoregulatory markers in septic patients’ plasma samples. Finally, Chapter 7 discusses the 
future direction of clinical immunoassays on the microring resonator platform.  
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Figure 1.1 a) Scanning electron microscopy image of a microring. Light from a tunable diode 
laser is directed through the linear waveguide and couples to the circular microring resonator when 
resonance conditions are met. b) Schematic diagram illustrating capture antibodies (yellow) 
immobilized on a microring, along with the transmission spectrum showing the characteristic dips 
at the resonance wavelength. Upon analyte (red) binding to capture antibodies on the microring 
surface, changes in refractive index leads to a shift in the transmission spectrum (from blue to red 
traces). The microring resonator instrumentation monitors the relative wavelength shift to produce 
the output sensogram in real-time. Figure adapted from Washburn, et al.(26) 
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Figure 1.2 Diagram illustrating the four different phases of translational research, where each 
phase in the process are interconnected with one another through constant assessment at each phase. 
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Chapter 2: 
Single Domain Antibodies for the Detection of Ricin using 
Silicon Photonic Microring Resonator Arrays 
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2.1 Abstract 
Ricin is a lethal protein toxin derived from the castor bean plant. Given its notorious 
history as a biowarfare agent and homicidal weapon, ricin has been classified as a category B 
bioterrorism agent. Current ricin detection methods based on immunoassays lack the required 
sensitivity and specificity for many homeland security surveillance applications. Importantly, 
many conventional antibody-based methodologies are unable to distinguish ricin from RCA 120, 
a non-toxic protein also found in the castor bean plant. Single domain antibodies (sdAbs), which 
are recombinantly derived from immunized llamas, are known to have high affinities for ricin A 
or B chains, and low cross-reactivity with RCA 120. Herein, we demonstrate the use of silicon 
photonic microring resonators for antibody affinity profiling and one-step ricin detection at 
concentrations down to 300 pM using a 15 minute, label-free assay format. These sdAbs were 
also simultaneously compared with a commercial anti-RCA IgG antibody in a multicapture 
agent, single target immunoassay using arrays of microrings, which allowed direct comparisons 
of sensitivity and specificity. A selected sdAb was also found to exhibit outstanding specificity 
against another biotoxin, saporin, which has mechanism of action similar to ricin. Given the 
rapidity, scalability, and multiplexing capability of this silicon-based technology, this work 
represents a step toward using microring resonator arrays for the sensitive and specific detection 
of biowarfare agents. 
2.2 Introduction 
Since ancient times, biological agents have been used as weapons by both militaries and 
terrorist organizations.(1) The use of ricin was considered by both the US and British militaries 
in both the First and Second World Wars, and was also employed in the infamous 1978 poisoned 
umbrella assassination of Bulgarian dissident Georgi Markov.(1, 2) More recently, the anthrax-
containing letters sent to media outlets and two U.S. Senators in 2001 in the aftermath of 9/11 
attacks, and similar attacks in 2003 and 2004, brought bioterrorism surveillance to the forefront 
of homeland security efforts.(1) Accordingly, there are pressing needs to develop robust 
analytical tools for the detection of ricin, and other potential biowarfare agents. 
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Ricin is a ~60 kDa proteinaceous toxin derived from the seeds of the castor bean plant, 
Ricinus communis.(3) The castor bean plant is grown worldwide and is the main raw material for 
production of castor oil, which has a broad range of industrial and medical applications.(2) As a 
byproduct of oil production, ricin is easily obtainable in large quantities,(2, 4) fueling fears that 
this agent could easily fall into the hands of terrorist organizations. A type 2 ribosome 
inactivating protein (RIP), ricin’s structure consists of an A chain and B chain linked by disulfide 
bonds.(3, 5, 6) The B chain is a lectin that binds to the galactose residues of glycoproteins and 
glycolipids on the cell surface, which facilitates ricin entry into the cytosol.(6) The chains are 
cleaved apart, and the A chain depurinates an adenine residue from the 28S rRNA of ribosomes 
at a rate of ~1500 ribosomes/min, which leads to inhibition of protein synthesis and eventually 
causes cell death.(3) 
The lethal dose of ricin varies dramatically depending upon the route of exposure, but 
inhalation represents the most dangerous mode, with a median lethal dose (LD50) of 3-5 μg/kg 
for inhalation versus 20 mg/kg via ingestion. This high lethality, ease of extraction, and high 
accessibility of ricin led to its classification as a category B bioterrorism agent by the Centers of 
Diseases Control and Prevention (CDC).(7)  
At present, common approaches for ricin detection includes polymerase chain reaction 
(PCR),(8-10) assays measuring the catalytic activity of ricin,(11-13) , and immunoassays.(14-20) 
Both PCR and catalytic activity assays are indirect methods for detecting ricin. PCR only detects 
nucleic materials from the plant origin of the toxin, and therefore is not applicable to detect 
purified ricin,(21, 22) while catalytic activity assays lack specificity towards ricin, since the 
catalytic activity of all RIPs is similar.(21, 23) Because of these limitations, most studies in the 
literature have utilized immunoassays for ricin detection. Immunoassays generally rely upon 
antibody recognition elements and can be used in a variety of formats, including 
radioimmunoassays,(14) enzyme-linked immunosorbent assays (ELISA),(15) 
electroluminescence,(16) fluorescent-based flow cytometry,(17) optical waveguide sensors,(18) 
surface plasmon resonance (SPR),(19) and colorimetric hand-held assays,(20) Importantly, the 
broad reliance upon immunoaffinity methods has generated strong interest in developing stable 
and robust antibodies that are specific for ricin.(23-25) 
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One limitation to ricin immunoassay development is that polyclonal immunoglobulin G 
(IgG) antibodies often do not have high specificity for ricin, and although monoclonal antibodies 
have improved specificity, they also have limited stability.(26) An alternative to conventional 
IgG antibodies is a class of recombinant antibodies known as single-domain antibodies (sdAb). 
sdAbs are derived from a special class of heavy-chain antibodies, which are found in animals of 
the Camelidae family, and also in sharks.(27-31) Unlike IgG antibodies, which consist of two 
heavy chains and two light chains linked by disulfide bonds, sdAbs do not have light chains, thus 
only a variable domain (VHH) on the heavy chain is responsible for antigen binding.(28, 29) 
This VHH region can be cloned and expressed as a recombinant sdAb,(27) with ten times lower 
molecular weight (~15 kDa),(27, 30) as compared to a standard IgG. Importantly, sdAbs are 
robust to heat and chemical treatment as they can refold to maintain their antigen affinity after 
denaturation.(29,32) These properties make sdAbs attractive capture agents for immunoassays of 
various formats. Anderson et al.(27) have recently developed a series of anti-ricin sdAbs and 
demonstrated their high affinity, specificity, and robustness in ELISA and bead-based 
immunoassay formats. These sdAbs were selected from a phage display library constructed by 
extraction of the mRNA of heavy chain antibodies in lymphocytes of immunized llamas, 
followed by PCR amplification to clone resulting sdAb genes into a phage display vector, and 
transformed to E. coli cells for antibody production.  
In this paper, we demonstrate the applicability of anti-ricin sdAbs for agent detection on a 
label-free microring array detection platform. Silicon photonic microring resonators are an 
emerging class of chip-integrated sensors that have been used to detect a range of biomolecular 
targets: including protein and nucleic acid biomarkers,(33-40) and viruses.(41) Microring 
resonators are refractive index-based sensors that are sensitive to the local environment near the 
microring surface. When the surface is modified with capture agents, such as antibodies, the 
binding of the target antigen is readily detected as a shift in the resonance wavelength supported 
by the microcavity. These changes are monitored as a function of time and used to quantify the 
amount of analyte in solution, or alternatively used to interrogate the kinetics of binding 
interactions. In addition to the high surface sensitivity and analytical versatility, advantages of 
this silicon photonic sensing technology come from its genesis in well-established semiconductor 
fabrication methodologies, which make the sensors highly scalable, inherently multiplexable, 
and cost-effective. Herein, we demonstrate the applicability of this technology for the relatively 
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rapid and quantitative detection of ricin using sdAbs down to a concentration of 300 pM in a 
label-free assay format. Furthermore, we verify that the sdAbs are significantly more specific 
than a standard IgG antibody when challenged with the molecularly similar, but non-toxic ricin 
analogue RCA 120. Importantly, we feel this work establishes this silicon photonic as a useful 
platform for detection biowarfare agents, since the multiplexing capability and cost effective 
nature of the technology would lend itself well to network surveillance efforts in which large 
numbers of sensor arrays could be distributed as a network for autonomous environmental 
monitoring. 
2.3 Experimental section 
2.3.1 Materials 
Unless specified, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and 
used as received. 3-N-((6-(N′-isopropylidenehydrazino))nicotinamide)propyltriethoxysilane 
(HyNic Silane) and succinimidyl 4-formyl benzoate (S-4FB) were purchased from Solulink (San 
Diego, CA). Ricinus communis agglutinin II (ricin), Ricinus communis agglutinin I (RCA 120) 
and a polyclonal goat anti-RCA antibody were purchased from Vector Laboratories, Inc. 
(Burlingame, CA). Polyclonal Chicken anti-saporin was purchased from Advanced Targeting 
Systems (San Diego, CA). Single domain antibodies (sdAb) C8 and B4 used in the experiments 
were a generous donation from Drs. George Anderson and Ellen Goldman at the Naval Research 
Laboratory. Aniline and glycine were purchased from ACROS Organics (Geel, Belgium). Zeba 
spin desalting columns were purchased from Thermo Fisher Scientific (Rockford, IL).  
All buffers were made from purified water (ELGA PURELAB filtration system; Lane 
End, UK) and the pH was adjusted with 1 M HCl or 1M NaOH. Phosphate buffered saline (PBS) 
was reconstituted from Dulbecco’s phosphate buffered saline packets purchased from Sigma-
Aldrich (St. Louis, MO). The low pH glycine buffer consisted of 10 mM glycine and 160 mM 
NaCl adjusted below pH 3.0.  PBST-BSA buffer consisted of 0.1mg/ml bovine serum albumin 
(BSA) and 0.05% (v/v) Tween 20 in 10 mM PBS at pH 7.4. The sensor chip blocking buffer 
consisted of 2% (w/v) BSA and 0.01% (w/v) sodium azide in 10 mM PBS at pH 7.4. 
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2.3.2 Sensor chip layout and instrumentation 
The microring resonator instrument and sensor chips were acquired from Genalyte, Inc. 
(San Diego, CA). Instrumentation and sensor chips designs have been previously described in 
detail.(33, 42) Briefly, the sensor chips are 6 mm×6 mm in size, and fabricated from silicon-on-
insulator wafers. Each chip consists of 32 microrings adjacent to linear waveguides. The entire 
chip is spin-coated with a perfluoropolymer cladding, with annular openings etched to expose 24 
rings to be used as sensors exposed to solution, while the remaining 8 rings are left under the 
cladding to serve as thermal control rings to correct for temperature drift. Light from a tunable 
external cavity laser in the instrument (wavelength centered at 1560 nm) interrogates each 
individual microring via grating couplers placed at the edge of the chip. The scan speed of the 
system is ~250 ms/ring with the entire array interrogated every ~9 seconds. 
2.3.3 Antibody immobilization on sensor chip surface 
Sensor chips were batch-functionalized by the following procedures: The chips are first 
cleaned for 30 s in piranha solution (3:1 ratio of concentrated sulfuric acid to 30% hydrogen 
peroxide), then rinsed with copious amount of distilled water and dried under a stream of 
nitrogen (Caution! Piranha solutions are extremely dangerous, reacting explosively with trace 
quantities of organics.). A 20 μL drop of a 1 mg/ml HyNic silane solution in 95% ethanol and 
5% N,N-dimethylformamide (DMF) was spotted on the surface of each sensor chip for 30 min, 
after which the chips were rinsed in 100% ethanol and dried under nitrogen to remove the excess 
HyNic Silane. 
Separately, antibodies were conjugated with S-4FB molecules by first buffer exchanging 
the antibodies into 100 mM pH 6.0 PBS using Zeba spin desalting columns. The resulting 
concentration of antibodies in PBS was measured using the NanoDrop spectrophotometer 
(Thermo Fisher Scientific, Wilmington, DE). After the concentration was determined, a five-fold 
molar excess of S-4FB (0.1 mg/ml in DMF) was added and allowed to incubate at room 
temperature for 2 hrs. Unreacted S-4FB was then removed by buffer exchanging antibodies into 
100 mM pH 7.4 PBS using the Zeba spin columns. The final concentration of the S-4FB-
modified antibodies was again determined by the NanoDrop spectrophotometer and adjusted to 
50 µg/ml.  
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Immediately before attachment to sensor chip surface, 4FB-modified antibodies were 
diluted to 25 µg/ml in PBS containing 100 mM aniline.(43) Approximately 1 µl aliquots of 4FB-
modified antibodies were deposited on specific microrings on the sensor chip surface with the 
aid of a stereo microscope to direct spotting positions, while a selected set of rings were blocked 
with 2% w/v BSA (unexposed to any antibodies) to serve as control rings. The antibody solution-
coated chips were then placed in a saturated humidity chamber overnight at room temperature. 
Afterwards, the sensor chips are immersed in chip blocking buffer overnight to block the chips 
surfaces prior to performing binding or detection experiments. 
2.3.4 Assay procedures 
Saporin, ricin and RCA 120 standard solutions were made via serial dilution of stock 
solutions in PBST-BSA. For each assay, a chip was placed in a holder with a two-channel 
microfluidic set-up defined by a Mylar gasket sandwiched between the holder and a Teflon lid. A 
syringe pump was used to control solution flow across 12 active sensor rings in each of two flow 
channels, the schematic of which was described in a previous publication.(33) Assays were 
conducted at 30 µl/min flow rate. Before each assay run, glycine buffer was flowed across the 
chip surface for 2 min to remove excess blocking BSA, before establishing a stable baseline by 
flowing PBST-BSA running buffer for at least 4 min. The analyte solution is then flowed across 
the chip for 10 min, followed by a 5 min PBST-BSA rinse. Each sensor chip is used only once 
without regeneration. 
2.3.5 Data analysis 
All microring responses were corrected for baseline thermal drift using the microrings 
occluded by the cladding layer as references. Each active microring signal was also corrected by 
setting the response of one blank control ring unmodified with antibodies as the “zero” reference 
to the response of antibody-modified rings. The initial slopes for all the sensograms of ricin 
standards and unknown samples were determined by a linear regression fit of the first five 
minutes upon binding of ricin to the sdAb immobilized on the microrings, after which the 
resulting slopes were averaged among the replicated measurements of each sdAb-modified ring 
exposed to the same sample. OriginPro 8.5.1 (OriginLab Corporation, Northampton, MA) was 
used to fit a linear regression plot to correlate the initial slopes with concentration of the ricin 
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standards in the calibration curve, while the concentration of the unknown sample was quantified 
by interpolating its corresponding initial slope on the calibration curve. 
2.4 Results and discussion 
As specificity towards ricin is of great importance when developing assays for this target 
our initial efforts focused on evaluating the reactivity and cross-reactivity of sdAbs towards ricin 
and RCA 120, respectively. The molecular weight of ricin is ~60 kDa and it sometimes referred 
to as RCA 60. Meanwhile, as its name suggests, RCA 120 is twice the mass of ricin, having a 
tetrameric structure that is >80% homologous to ricin, yet is much less toxic.(44) A 
commercially available goat anti-RCA IgG was arrayed next to the sdABs B4 and C8, as well as 
the BSA blocked control rings. All of the microrings were then simultaneously exposed to 10 nM 
RCA 120. In a separate experiment, an identically arrayed sensor chip was exposed to 10 nM 
ricin. Figure 2.1 shows the responses of the arrays to both RCA 120 and ricin. All of the ricin 
and RCA-specific capture agents show strong responses to ricin; however, the anti-RCA IgG 
shows a much larger response to RCA 120 as compared to the sdAbs, verifying the enhanced 
specificity of the sdAb capture agents.  
In addition to specificity for ricin over RCA 120, we also investigated the cross-reactivity 
of the C8 sdAb against saporin, another RIP found in nature. Initially, we tested saporin against 
an anti-saporin antibody to confirm binding affinity of the molecule (Figure 2.2). Using a chip 
with all rings immobilized with C8 sdAbs, we consecutively exposed the rings to 30 nM saporin 
follow by 30 nM ricin. As shown in Figure 2.3, responses from the C8 immobilized microrings 
further demonstrate the specificity of this sdAb towards ricin over another RIP. 
These cross-reactivity and detection results further support previous work by Anderson et 
al., indicating that among sdAbs C8 and B4, C8 has the highest binding response to ricin while 
B4 have the lowest non-specific binding to RCA 120.(27, 30) Having established that sdAb C8 
offered good specificity and sensitivity, we sought to demonstrating quantitative detection 
capabilities of ricin on our sensor platform. We flowed a set of standard ricin solutions, prepared 
in PBST-BSA to concentrations of 10 nM, 3 nM, 1 nM, 0.3 nM and 0 nM, across an array of 
microrings functionalized with sdAb C8. The binding responses to each concentration of ricin 
interacting with eight microrings per sensor chip were then recorded and corrected using the 
BSA-blocked rings, as shown in Figure 2.4. Response for four representative microrings are 
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shown in Figure 2.4 for the sake of clarity; however the average initial slopes and standard 
deviations for all eight sensors are provided in Table 2.1.  
We previously showed the ability to perform rapid, label-free quantitation based upon the 
initial slope of binding response upon introduction of the antigen-containing solution.(33) Using 
the data from Figure 2.4, but including fits to all eight binding curves recorded at each 
concentration of ricin, we created a calibration plot that could be used for determination of an 
unknown. Figure 2.5 shows the resulting calibration curve. We then utilized this calibration 
curve to determine the concentration of a solution having an unknown ricin concentration 
prepared in PBST-BSA. Comparison of the sensor response with the calibration curve allowed us 
to determine the unknown concentration to be 4.20±0.43 nM. This value and error, determined as 
the 95% confidence interval for the n=8 measurement, was in good agreement with the “as 
prepared” value of 4.5 nM.  
Finally, we determined the limit of detection for label-free ricin detection by analyzing 
the noise present in the measurement. Specifically, we determined assay “slope noise” (σ) of the 
running buffer baseline, which is a measure of how precisely we can determine the initial slope 
of the sensor binding response. Using the determined value of 0.09 pm/min for this system, we 
then determine the limit of detection as 3σ (~0.27 pm/min). Evaluation of this noise level against 
the ricin standard binding curve points to an overall limit of detection of 200 pM. Furthermore, it 
is worth noting that we have previously shown that assay sensitivity, and specificity, can be 
further increased by using a secondary capture agent and tertiary binding events.(34-36) 
For applications in biodefense, a rapid, real-time ricin detection system is needed to 
ensure a prompt and efficient response capacity. Herein, we demonstrate a label-free detection 
methodology that achieves a relevant limit of detection within a rapid (<15 min) assay format.  
Admittedly, the matrix described in this manuscript is quite proteinaceous, but relatively well-
controlled compared to that encountered in many analytical matrices. However, the detection of 
airborne agents is a rather unique potential application area, as samples collected using air 
filtration are typically resuspended in a convenient buffer of choice. As mentioned above, ricin 
and many other biowarfare agents pose very high inhalation threats, and therefore air and surface 
sampling, both of which often involve suspension in a neat buffer solution, are commonly 
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utilized for these agents.(8, 45, 46) This practical operation procedure adds support to the utility 
of this rapid and label-free, buffer-based assay for ricin and its potential for future deployment as 
sensor networks for biowarfare agent surveillance. 
2.5 Conclusions 
In this work, we demonstrated that silicon photonic microring resonator arrays are a 
powerful and promising tool for detecting biowarfare agents such as ricin. Our evaluation of 
anti-ricin sdAbs on the microring arrays platform is consistent with the previous reports that 
show sdAbs to have selective affinity towards ricin, yet minimal cross-reactivity with the non-
toxic analogue RCA 120. We further established specificity for the sdAb C8 againts saporin, 
another potential biotoxin that acts through a similar catalytic mechanism. Using the sdAb C8 as 
a capture agent, we also illustrated a rapid, real-time, one-step quantitative approach of ricin 
detection, detecting a concentration of 300 pM in a 15 minute, label-free assay format. Future 
efforts will focus on further improving assay performance in terms of specificity and sensitivity, 
as well as the creation of multiplexed detection panels towards the goal of surveillance for 
multiple agents within environmental matrixes. 
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Figure 2.1 Responses of a 3-capture agent sensor array exposed to 10 nM of a) RCA 120 and b) 
ricin. sdAb clones C8 and B4 both show greater selectivity for ricin compared to the goat anti-
RCA IgG, which shows the largest response to RCA 120. Both sdAb clones show a significantly 
reduced response to RCA 120 while displaying good binding responses to ricin. In both sensing 
experiments, blank control rings show insignificant levels of non-specific binding. 
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Figure 2.2 Response of microring arrays immobilized with polyclonal chicken anti-saporin 
antibodies (blue lines) upon addition of 30 nM saporin. Dark grey lines indicate thermal control 
rings. 
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Figure 2.3 Response of sdAb C8 upon addition of 30 nM saporin, follow by addition of 30 nM 
ricin (Red lines). Arrows indicate injection of solutions, while the asterisk indicate a PBST-BSA 
buffer rinse step. Dark gray lines indicate thermal control rings. 
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Figure 2.4 Concentration-dependent binding response of ricin as a function of target 
concentration. Each measurement was made eight times redundantly on the same sensor chip, 
functionalized identically with sdAb C8. Following the establishment of an initial baseline by 
equilibrating with PBST-BSA running buffer, ricin-containing solutions were flowed across the 
array (staring at t = 5 min) and persisted for a total of 10 minutes. 
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Figure 2.5 Calibration curve illustrating the concentration-dependent response of sdAb C8 
functionalized microrings to solutions of various concentrations. Real-time binding curves were 
obtained (as in Figure 2.4) for samples prior to the analysis of a prepared solution containing an 
unknown amount of ricin. The sensor response for the unknown solution was then compared 
against the standard calibration curve, allowing for quantitative detection. Error bars represent 
the 95% confidence interval from n=8 measurements. 
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Ricin concentration  
(nM) 
Average initial slope 
for n=8 rings  
(Δpm/min) 
Standard deviation 
for n=8 rings  
(±Δpm/min) 
95% Confidence 
interval 
(±Δpm/min) 
0 -0.07 0.09 0.08 
0.3 0.2 0.2 0.14 
1 2.6 0.8 0.63 
3 6.8 1.0 0.81 
10 18.5 0.7 0.66 
 
Table 2.1 Average initial slopes, standard deviations and initial slopes at 95% confidence 
interval for n=8 rings between 0-10 nM concentrations of ricin. 
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3.1 Abstract 
The analysis of disease-specific biomarker panels holds promise for the early detection of 
a range of diseases, including cancer. Blood-based biomarkers, in particular, are attractive targets 
for minimally-invasive disease diagnosis. Specifically, a panel of organ-specific biomarkers could 
find utility as a general disease surveillance tool enabling earlier detection or prognostic 
monitoring. Using arrays of chip-integrated silicon photonic sensors, we describe the simultaneous 
detection of eight cancer biomarkers in serum in a relatively rapid (1 hour) and fully automated 
antibody-based sandwich assay. Biomarkers were chosen for their applicability to a range of 
organ-specific cancers, including disease of the pancreas, liver, ovary, breast, lung, colorectum, 
and prostate. Importantly, we demonstrate that selected patient samples reveal biomarker 
“fingerprints” that may be useful for a personalized cancer diagnosis. More generally, we show 
that the silicon photonic technology is capable of measuring multiplexed panels of protein 
biomarkers that may have broad utility in clinical diagnostics. 
3.2 Introduction 
The development of targeted protein-based diagnostics promises to increase the 
degree of biomolecular detail that can be gleaned into the state of disease. For example, 
biomarker panels have been investigated as a means to provide more personalized and 
effective treatment for cancer.(1, 2) Although much work has been accomplished to 
discover putative biomarkers and biomarker panels, validation and clinical deployment of 
diagnostic biomarker panels remains to be achieved.(3-5) Typically, clinical assays for 
protein biomarkers rely on immunoassays such as the enzyme-linked immunosorbent assay 
(ELISA), which is traditionally designed to measure one biomarker at a time. However, 
given the diagnostic potential of multiplexed analyses, there is an increasing emphasis on 
the development of technologies capable of simultaneously detecting multiple protein 
targets from within a single sample, with the bead-based Luminex platform being the most 
commercially successful. Many emerging technologies leverage advances micro- and 
nanoscale fabrication technologies to create small footprint sensors that can be configured 
into multiplexed sensor arrays.(6-9) 
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To this end, our own group has been developing a scalable silicon photonic 
technology detection platform that can be readily configured into multiplexed detection 
arrays for to create multiplex sensors that can measure multiple proteins from a given 
sample.(10, 11) Silicon photonic microring resonators belong to a larger class of refractive 
index-responsive “whispering gallery resonators” (12) and this chip-integrated geometry 
leverages robust semiconductor fabrication methods to create multiplexable sensor arrays. 
Light is coupled into microring resonators from adjacent linear waveguides only under 
conditions of optical resonance, as described by: 
mλ = 2πrneff 
where m is an integer, λ is the wavelength of light, r is the radius of the ring, and neff is the 
effective refractive index of the waveguide mode. When functionalized with target-specific 
capture agents, binding induced changes in the local refractive index at the sensor surface 
can be used to sensitively quantitate the presence of a range of analytes. 
The scalability of silicon enables the facile creation of microsensor chips containing 
multiple sensors on a given chip. Experiments described in this paper were performed on 
sensor chips with 32 active microring sensors, with two additional sensors used to correct 
for thermal drift. Using these arrays, we create a microsensor chip that can detect eight 
different analytes, each measured in quadruplicate, as illustrated in Figure 3.1. As described 
in greater detail in the experimental methods section, antibodies were attached to the 
surface via the DNA-encoded antibody method,(13, 14) which provides a robust approach 
for creating on-demand antibody arrays. The following eight biomarkers were targeted on 
account of their previously reported correlation with organ-specific cancer: α-fetoprotein 
(AFP; liver and germ cell cancers(15)); activated leukocyte cell adhesion molecule 
(ALCAM; breast cancer(16)); cancer antigen 15-3 (CA15-3; breast cancer(15)); cancer  
antigen 19-9 (CA19-9; pancreatic, colorectal, and ovarian cancers(15, 17)); cancer antigen-
125 (CA-125; ovarian cancer(15, 18)); carcinoembryonic antigen (CEA; colorectal and 
pancreatic cancers(19-21)); osteopontin (ovarian and liver cancers(18, 22)); and prostate 
specific antigen (PSA; prostate cancer(23)). Within our selected 8-plex panel, five 
biomarkers are FDA-approved biomarkers (AFP, CA15-3, CA-125, CEA, PSA).(24) These 
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biomarkers were also convenient targets because they have broad relevance across diverse 
organ-specific cancers and also have a good selection of commercially available antibodies. 
It is important to note that many of these biomarkers have been observed in other 
types of cancer and even within a single organ-type of cancer their elevation is not 
ubiquitous, which reflects underlying heterogeneities in disease mechanism. In fact, patient 
heterogeneity often complicates the universal diagnostic utility of any single biomarker. 
Moreover, the validation of any biomarker(s) requires the analysis of many diverse patient 
samples, which underscores the need for robust and automated biomarker screening tools. 
In this manuscript our focus is not on the biological relevance of specific biomarkers, but 
rather the demonstration that the silicon photonic detection technology can be used for 
analyse panels of protein biomarkers from within clinically-relevant samples. 
3.3 Results and discussion 
In contrast to most other immunoassay technologies which only offer endpoint 
readout, microring resonators offer a unique real-time monitoring capacity that is extremely 
enabling in the assay development process. Specifically, every step of the assay, including 
antigen-capture antibody and tracer antibody binding, and the entirety of the signal 
enhancement process can be followed in real time as each of these steps causes a shift in 
resonance wavelength. We have previously demonstrated that this breadth of measurement 
capability can enable an extended dynamic range of detection, an important consideration 
when measuring multiple analytes each with a particular concentration range of 
interest.(25) Additionally, observation of direct binding of antigens and capture antibodies 
tremendously expedites the screening and identification of capture agents with the required 
binding affinity and specificity. While not a major focus of this manuscript, this complete 
assay development capability offers a significant advantage in that the same technology can 
be utilized throughout the entire assay design, validation, and (eventually) deployment 
process. 
Figure 3.2 shows how microring resonator arrays can be used to construct a 
multiplexed biomarker detection panel, including the ability to reveal antibody cross 
reactivity. Figures 3.2a and 3.2b represent eight separate experiments showing primary and 
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tracer recognition, respectively, of single biomarkers in buffer. In Figure 3.2a, each antigen 
was added individually in order and the primary binding was observed. Most of the capture 
antibodies show a specific response for only the specified target; however, noticeable cross 
reactivity was observed for the analytes CA19-9 and CA15-3. Upon the introduction of 1 
kU/mL CA19-9, the appropriate anti-CA19-9-functionalized rings (cyan) respond, but the 
anti-CEA-functionalized rings (orange) also show a resonance shift, indicating non-specific 
target binding to this capture antibody. Similarly, addition of 1 kU/mL of CA15-3 generated 
resonance shifts from not only the anti-CA15-3-functionalized sensors (purple), but also 
from the anti-CEA- (orange) and anti-CA19-9-functionalized (cyan) sensors. 
In a continuation of these single biomarker studies, we then tested tracer antibodies, 
which can form a highly selective sandwich immunocomplex specific for the targeted 
biomolecule. Figure 3.2b shows the sensor responses upon the sequential addition of 1 
µg/mL of each tracer antibody, which followed the introduction of a single biomarker for 
the primary binding step (Figure 3.2a). Interestingly, the addition of every tracer antibody 
shows a selective response, indicating on-target recognition, with one exception. The anti-
CA 15-3 tracer was also observed to bind to anti-CA 19-9-functionalized rings, which had 
also showed an apparently non-specific response to CA 15-3. In a separate experiment (not 
shown) we flowed the anti-CA 15-3 tracer antibody alone (no antigen) over the array of 
capture antibodies, suggesting that the response is a function of the biomarker sample itself. 
Upon consulting the product literature provided by the vendor, CA 19-9 is a known 
contaminant in the CA 15-3 sample, which explains this response and provides confidence 
in the overall fidelity of our 8-plex biomarker detection panel. Moreover, arrays of silicon 
photonic sensors and the real-time analysis capability provide significant benefits in terms 
of assay development, optimization, and troubleshooting that will likely be helpful for 
reagent screening and assay validation even if they are to be used with alternative detection 
methodologies. 
After determining that the 8-plex assay had sufficient specificity, we proceeded to 
make measurements of biomarkers in human serum samples. In order to obtain a detection 
of limit at the clinically relevant levels, we employed a multilayer antibody signal 
enhancement method similar to what our group(26) and Gauglitz et al.(27) have used for 
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creating protein multilayers on a surface. Except for a limited use by Anderson et al.,(28) 
this technique has not been previously applied to enhance the signal of an immunoassay in 
the literature.  
Figure 3.2c illustrates this methodology on the microring resonator silicon surface. 
Following the binding of the primary antigen and biotinylated tracer antibody, a solution 
of PE-labelled anti-biotin antibodies is introduced and a binding response is only measured 
on microrings that have the fully assembled sandwich immunocomplex (capture antibody-
antigen-tracer antibody). Biotinylated anti-PE antibodies are then introduced, which bind 
to the PE labels of the anti-biotin antibody. This process can be repeated with cycling 
between separate solutions containing either PE-labelled anti-biotin or biotinylated anti-PE 
antibodies giving an enhanced shift in the resonance wavelength shift that correlated with 
the initial concentration of antigen in solution. It is worth noting that the Maverick M1 
instrumentation utilized in these experiments features completely automated fluid handling, 
which facilitated this multi-step signal enhancement strategy. For our assays, we used a 
maximum of six steps (3 multilayer cycles), though some biomarkers could be detected 
with fewer. Notably, negative control experiments revealed that the signal enhancement 
strategy in the absence of target did not contribute any non-specific sensor response (Figure 
3.3). Furthermore, by quantitating in buffer, as opposed to sensor matrix, this sandwich 
assay format was immune to the sample matrix effects seen in the primary binding 
response. 
Figure 3.2d shows the real-time shifts in resonance wavelength during an entire 
representative 8-plex biomarker assay from a representative human serum sample. The 
diluted serum sample was flowed across a pre-functionalized microring resonator array for 
a total of 30 minutes to allow primary antigen binding. After 30 minutes, the flow is 
switched to running buffer and the surface rinsed for 20 minutes. Note that there is a large 
bulk refractive index shift that is observed upon introduction of serum, which is confirmed 
by its reversal upon switching running buffer. A cocktail of all eight tracer antibodies were 
then flowed across the surface for 15 minutes, followed by a 5 minute rinse with running 
buffer. The multilayered signal enhancement scheme was then invoked with 2 minute 
cycles in the PE-labelled anti-biotin and biotinylated anti-PE antibodies.  
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 After assay development and validation of specificity, we then created standard 
curves to be used for biomarker quantitation. Solutions containing known concentrations 
of biomarker standards were prepared and analysed using the 8-plex microring array. The 
total relative shift during the secondary enhancement is plotted as a function of 
concentration, with a calibration curve for each antigen presented in Figure 3.4. Further 
details about the calibration analysis and fitting parameters is given in the Experimental 
Methods section. 
 Following the generation of calibration curves, we next moved to quantitate the 8-
plex biomarker panel in a handful of representative human serum samples. Specifically, we 
analysed commercially-available samples from patients generically diagnosed with 
pancreatic, liver, ovarian, breast, lung, colorectal, and prostate cancer, as well as a sample 
from a healthy patient. Figure 3.5 shows the real-time resonance shifts for each of the entire 
8-plex assays. The resonance shift during the secondary, protein multi-layer enhancement 
regime was measured and compared against the calibration curves to determine the serum 
concentrations of each of the respective antigens (Table 3.1). 
For the sake of comparison, the sensor responses of each biomarker determined from 
the cancer patient samples were divided by the response of the same biomarker measured 
in the healthy sample to generate a relative index of expression. That is to say that a relative 
index of 15 means that the biomarker level is elevated 15-fold over the healthy sample. 
This mechanism of data presentation is helpful as some biomarkers, such as ALCAM, have 
uniformly higher concentrations in all samples and therefore the importance in absolute 
concentrations is highly variable across this set of biomarkers. This indexing approach 
seems reasonable given that these markers are known to be elevated in the case of organ-
specific cancer. 
In Figure 3.6 we plotted relative indices across the 8-plex panel for each patient that 
revealed organ-specific biomarker “fingerprints” for these seven samples. For example, the 
known pancreatic cancer biomarker CA 19-9 shows the greatest level of elevation in the 
pancreatic cancer sample. Similarly, CA 15-3 and PSA show the largest elevations in breast 
and prostate cancer, respectively. For the liver cancer sample, AFP and osteopontin, both 
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known to be elevated in some liver malignancies, showed elevated levels. However, we 
also see examples where biomarkers are not elevated as have been reported in the literature. 
CA-125, a putative ovarian cancer biomarker, is not elevated in the ovarian cancer sample. 
Also, both CEA, a colorectal cancer marker, and ALCAM, a breast cancer marker, have 
relatively stable levels across all of the patient samples and are not elevated in breast or 
colorectal samples. 
Importantly, we are not making any claims about the diagnostic of any of these 
markers. Rather we are reporting on the development of a silicon photonic technology that 
has the capability to robustly perform analyses of multiplexed panels of serum biomarkers. 
From a biological perspective, though, there are many reasons why the diagnostic utility of 
specific biomarkers might not strictly be observed in these (and other) serum samples. The 
patient-to-patient heterogeneity of cancers is well-documented and genetic and phenotypic 
differences can lead to wide disparities in secreted biomarker signatures. Perhaps the best 
instance of underling disease heterogeneity compromising the value of single biomarker-
based diagnostics is the example of PSA, of which an overreliance on this assay for 
screening purposes can lead to over diagnosis and overly aggressive treatment.(29) 
Moreover, the limited specificity of many single disease biomarkers greatly restricts their 
independent diagnostic utility,(30) but rather suggest defined roles in screening and 
monitoring. Though taken together, panels of mildly specific serum biomarkers might, if 
recorded longitudinally using cost effective, multiplexed technologies, be very effective in 
the early detection of malignancies that could then be localized via more highly specific 
clinical means. 
3.4 Experimental methods 
3.4.1 Materials 
Succinimidyl 4-formylbenzoate (S-4FB), succinimidyl 6-hydrazinonicotinamide 
acetone hydrazone (S-HyNic), and 3-N-((6-(N'-Isopropylidene-hydrazino))nicotinamide)-
propyltriethyoxysilane (HyNic Silane) were purchased from SoluLink (San Diego, CA). 
Custom DNA oligonucleotides were synthesized by Integrated DNA Technologies 
(Coralville, IA). A list of all antigens and antibodies (capture and detection) purchased and 
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used for eight-plex experiments are listed in Table 3.2. NHS-PEG4-Biotin, Zeba spin filters, 
and Starting Block were purchased from Pierce (Rockford, IL). NHS-PEG4-Biotin was 
dissolved in N,N-dimethylformamide (DMF) to make a 20 mM stock solution. Vivaspin 
molecular weight cutoff filters (50,000 and 5,000 Da MWCO), were obtained from GE 
Healthcare (Waukesha, WI). Anti-biotin antibody conjugated to phycoerythrin (anti-biotin 
PE) and biotinylated anti-phycoerythrin (anti-PE biotin) were obtained from eBioscience 
(San Diego, CA). Phosphate buffered saline (PBS), with a standard 10 mM phosphate ion 
concentration, was reconstituted from Dulbecco’s phosphate buffered saline packets 
purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals were obtained from 
Sigma-Aldrich and used as received. Human serum samples from cancer patients were 
purchased from Innovative Research, Inc. (Novi, MI) and Asterand, Inc. (Detroit, MI).  
Buffers were made with purified water (ELGA PURELAB filtration system; Lane 
End, UK), and the pH adjusted as necessary with 1 M HCl or 1 M NaOH. For NHS-ester 
chemistry, A high phosphate PBS buffer with 100 mM phosphate (100 mM PBS) was made 
to be 150 mM NaCl, 22.5 mM monobasic sodium phosphate, and 77.7 mM dibasic sodium 
phosphate and then pH-adjusted to either pH 7.4 or pH 6.0. PBS with 0.05% Tween-20 
(PBST) was made by adding Tween-20 to standard PBS buffer (Dulbecco’s formulation). 
PBST with Starting Block (PBST-SB) was made by adding 1% Starting Block to PBST 
buffer and then adding 0.01% sodium azide as a preservative. All solutions were degassed 
under vacuum with concurrent sonication before being flowed across the sensor surface. 
3.4.2 Instrumental setup and microchip design 
The instrument, sensor chips, and microring resonator measurement system was 
acquired from Genalyte, Inc. (San Diego, CA). The M1 version of the instrument offered 
optical detection performance equivalent to the previous version,(31) but with the enabling 
addition of full automation of fluidic flow with programming to allow sipping from a 96-
well plate. The chips used in these experiments are 4 × 6 mm microchips with 34 microring 
sensors—32 active sensor rings and 2 thermal controls, which are rings covered by a 
polymeric cladding that allowed real-time correction of resonance shifts resulting only from 
temperature fluctuation. All measurements for these experiments were made with the 
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sensor chips loaded into a custom cell with microfluidic flow channels defined by a 0.007-
inch thick Mylar gasket with a U-shaped channel 400 µm wide. Solution was drawn from 
pre-loaded 96-well plates via the automated fluid handling system in the instrument.  
3.4.3 Surface functionalization with DNA 
Microring array substrates were first cleaned with piranha solution (3:1 H2SO4:30% 
H2O2) for 30 seconds followed by rinsing with water and drying under a stream of N2. To 
introduce reactive functional groups, substrates were covered with 20 µL of a 1 mg/mL 
solution of HyNic Silane (20 mg/mL HyNic Silane in DMF stock solution diluted to 1 
mg/mL with ethanol) for ~30 minutes, followed by rinsing with ethanol and then sonicating 
in ethanol for ~30 minutes. Chips were then dried with N2. Notably, the polymeric cladding 
layer confined surface functionalization to the annular openings surrounding microring 
sensors. 
Antibodies were attached to the sensor surfaces via DNA-DNA hybridization, as is 
described below. For this purpose, individual microring sensors were modified with 
specific single-stranded DNA oligonucleotides, the sequences of which were previously 
designed to ensure minimal cross-reactivity.(32) The sequences of all surface attached 
oligonucleotides (B, C, D, F, J, K, L, and M), are provided in Table 3.3. Single-strand 
oligonucleotides were synthesized with a 5′ amino terminal group to facilitate surface 
attachment via standard bioconjugate reactions. Oligonucleotides were first functionalized 
with S-4FB according to manufacturer (SoluLink) instructions, with an initial buffer 
exchange to 100 mM PBS pH 7.4 using 5 kDa MWCO filters and then subsequent reaction 
with a 20-fold molar excess of S-4FB in DMF. Solutions were allowed to react overnight 
at room temperature and were then buffer exchanged into 100 mM PBS pH 6.0 using 5 kDa 
MWCO filters to remove excess S-4FB reagent.  
Eight-plex chips were created by microspotting 4FB-functionalized DNA strands 
onto HyNic-functionalized microring resonator chips. Each chip had four microrings 
spotted with a unique DNA sequence (B, C, D, F, J, K, L, and M). Spotting was 
accomplished with a Nano eNabler spotting system from BioForce Nanosciences (Ames, 
IA). The 4-FB-modified DNA was diluted to a concentration of ~100 µM in 100 mM PBS 
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buffer pH 6.0 and mixed in a 1:1 ratio with dimethyl sulfoxide (DMSO). After spotting, the 
drops evaporated on a hot plate (~80 C) for five minutes and then incubated in a saturated 
humidity chamber overnight. The chips were then briefly rinsed in Starting Block, and then 
immediately in water. The chips were then again rinsed with fresh Starting Block and stored 
in PBST-SB until use.  
3.4.4 DNA-Antibody conjugate synthesis and sensor array encoding via self-assembly 
To create DNA-antibody conjugates, antibodies were functionalized with S-HyNic 
as previously demonstrated.(13) The sequences of oligonucleotides attached to antibodies 
(B′, C′, D′, F′, J′, K′, L′, and M′; with the prime denoting complementarity to the respective 
surface-attached sequence) are provided in Table 3.3. Again, each oligonucleotide had a 5′-
NH2 functionality. S-HyNic solutions, dissolved in DMF, was added in 20- to 30-fold molar 
excess to ~1 mg/mL antibody that had been buffer exchanged into 100 mM PBS pH 7.4 
with a Zeba spin filter. This reaction was allowed to proceed for at least two hours at room 
temperature. The HyNic presenting antibodies were then exchanged into 100 mM PBS pH 
6.0 with a Zeba spin filter to remove excess HyNic. 
DNA modified with 4FB was then added in >10-fold molar excess to the HyNic-
modified antibody and allowed to react overnight at 4 °C. The resulting DNA-antibody 
conjugates were then purified away from the excess 4FB-DNA using a Superdex 200 
10/300 GL column on an AKTA FPLC, both from GE Healthcare (Waukesha, WI). The 
separation was performed at 4 C with a PBS isocratic elution. Collected fractions were 
concentrated with 50 kDa MWCO filters to yield purified solutions of DNA-antibody 
conjugates. The final conjugate concentration was determined by measuring the differential 
absorption at 260 versus 280 nm, corresponding to the DNA and IgG, respectively, using a 
NanoDrop UV-Vis absorbance system (ThermoFisher Scientific, Wilmington, DE). The 
following conjugates were synthesized using the capture antibodies listed in Table 3.2, 
resulting in the following DNA-capture antibody combinations: B′-anti-AFP, C′-anti-
ALCAM, D′-anti-CA19-9, F′-anti-osteopontin, J′-anti-CA15-3, K′-anti-CEA, L′-anti-CA-
125, M′-anti-PSA.  
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To create multiplexed biomarker detection arrays, each of the DNA-antibody 
conjugates were combined into a single mixed with each conjugate at 5 µg/mL (except for 
L′-anti-CA-125, which was used at 1 µg/mL) in PBST. To each eight-plex, DNA-
functionalized microchip, 10 μL of DNA-antibody conjugate mixture was added to the 
surface of each chip and the array allowed to self-assemble. Chips were incubated overnight 
to enable maximum binding of the DNA-antibody conjugates to the DNA capture probes 
on the surface. Following overnight binding, the chips were rinsed and stored immersed in 
PBST-SB. 
3.4.5 Tracer antibody biotinylation 
Each of tracer antibodies was biotinylated to facilitate the layer-by-layer signal 
enhancement scheme. The ALCAM tracer was purchased as a pre-biotinylated polyclonal 
antibody. Each of the other tracer antibodies were first buffer exchanged into 100 mM PBS 
pH 7.4 via a Zeba spin column. A 20-fold molar excess of 20 mM NHS-PEG4-biotin was 
then added allowed to react for 2 h at room temperature. For the anti-AFP and anti-
osteopontin tracer antibodies, it was empirically determined that 5-fold and 50-fold molar 
excesses, respectively, gave the best performance. Excess NHS-PEG4-biotin was removed 
by buffer exchange using Zeba spin filter columns. Prior to use in the layer-by-layer signal 
enhancement scheme, the anti-PE biotin and anti-biotin PE antibodies were buffer 
exchanged into the PBST-SB.  
3.4.6 Eight-plex antigen analysis 
To generate calibration curves, all antigens were diluted in PBST-SB or 50% 
Starting Block/50% PBST-SB. Human serum samples were analysed after diluting to 33% 
in PBST-SB. The sensor array was placed into the fluidic cartridge and loaded into the M1 
instrument. For all assay steps, except for sample and biotinylated tracer antibody 
introduction, the flow rate was 30 μL/min. When the sample and biotinylated tracer was 
introduced, the flow rate was reduced to 15 μL/min to reduce consumption. PBST-SB was 
used as the running buffer and was flowed over the surface for ~5 minutes to establish a 
stable baseline. The sample was introduced and flowed over the chip for a total of 30 
minutes (200 μL of serum diluted 3-fold) before a 20 minute rinse with running buffer to 
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help remove non-specifically bound proteins for 20 minutes. A mixture of biotinylated 
tracer antibodies each at a concentration of 1 µg/mL was then flowed over the chip for 15 
minutes followed by a 5 minute running buffer rinse. For the layer-by-layer signal 
enhancement step, the solution flowing across the chip was repeatedly switched between 1 
µg/mL anti-biotin (PE) and 2 µg/mL anti-PE (biotin) for two minutes each, with a 15-
second running buffer rinse between each step. This process was repeated up to 3 times (six 
steps), yielding an enhanced signal magnitude for biomarkers present in the sample. 
Importantly, each of these steps was completely automated and did not require any under 
intervention during the assay. 
The difference in resonance wavelength shift before and after the signal 
enhancement step was determined and used for quantitation. Importantly, since the signals 
are measured only from this secondary step, resonance shifts from non-specific protein 
adsorption do not contribute to the analytical signal.  
Calibration curves were made to cover a range of biomarker concentrations relevant for 
clinical serum specimens, as shown in Figure 3.4. To conserve analysis time while avoiding 
possible interferences between antigens, calibrations were obtained simultaneously for CEA, 
ALCAM, AFP, and PSA. CA19-9 and CA15-3 calibrations were obtained together, but apart from 
the other antigens. By running a few concentrations of CA15-3 with no CA19-9 and vice versa, it 
was possible to obtain corrections for how the stock antigen solutions interfered with each other. 
Similarly, osteopontin and CA-125 calibrations were run together, but apart from the other 
antigens. Each point on the calibration curve represents one measurement on one chip based on 
the net shift in resonance frequency (pm) obtained from the tertiary amplification step. Because 
the tertiary amplification step consisted of 6 mini-steps (anti-biotin, anti-PE, anti-biotin, anti-PE, 
anti-biotin, anti-PE), it was possible to use a different region of the tertiary amplification curve for 
each antigen. This was important because some of the antigens tended to generate higher signals 
and would saturate the tertiary signal faster than the antigens that generated lower signal. For 
example, the ALCAM calibration curve had the largest range of quantitation when the shift was 
measured after only one of the amplification mini-steps. At later steps of the amplification, the last 
two points on the calibration curve became indistinguishable from each other. In contrast, CA15-
3 tended to display only small relative shifts, and thus using 6 amplification steps increased the 
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signal that could be observed. Incidentally, we have observed that amplification beyond about 6 
steps tends to increase the signal, but the noise increases proportionally leading to a relatively 
constant signal to noise ratio. The number of amplification steps used for each antigen’s calibration 
curve is given in Table 3.4.  
The error bars shown on the calibration curves were derived based on the standard 
deviation of the ring-to-ring measurements on a given chip or the chip-to-chip, whichever was 
larger. Chip-to-chip variability was determined by performing the identical assay on multiple 8-
plex chips, and this variability was calculated to have a coefficient of variation (CV) of 17%. This 
same error formula was applied to the relative signal index measurements used in Figure 3.6.  
Calibration curves were based on unweighted fits with either a linear model or a dose-
response model fit in OriginPro software package version 8.5. The dose-response equation used is 
given here: 
ݕ ൌ ܣ ൅ ሺܤ െ ܣሻ1 ൅ 10ሺ஼ି௫ሻ஽ 
 Calibration curves overlaid on data plots are shown in Figure 3.3. Calibration parameters 
are listed in Table 3.4.  The units for AFP, ALCAM, Osteopontin, CEA, and PSA are given in 
ng/mL whereas CA19-9, CA15-3, and CA125 are given in units/mL (U/mL). These labels are 
based on the units given from the commercially obtained antigen solutions. Table 3.1 lists the 
results of the calibration analysis for individual tested serum samples with reference to the upper 
and lower quantitation limits for the calibration curves listed in Table 3.5. A “—” indicates a 
measurement that was below the range of quantitation used for the calibration curve. A result with 
a “>” indicates that the measurement fell higher than the quantitation range used for the calibration 
curve.  CA-125 fell below the range of accurate quantitation in all samples, and so it is not listed 
on the table. A few of the samples still had measurable shifts even though the values fell below 
the range of quantitation. As a result, Figure 3.6 displays a relative index value for these antigens. 
This is a case of the limit of detection (LOD) being lower than the limit of quantitation (LOQ). 
In Table 3.1. the errors shows for each measurement are extrapolated from the standard 
deviation of the measurement signal via the calibration curve. In other words, y ± yerror is converted 
to x ± xerror, where yerror was determined using relative standard deviation, as described previously.  
46 
 
3.5 Conclusions 
The emergence of a number of disease-related biomarkers place an impetus on the 
development of robust diagnostic technologies of cost-effective and relatively rapid 
measuring levels of multiple biomarkers from within single patient sample. Using a silicon 
photonic microring resonator platform we demonstrate the multiplexed detection of eight 
cancer serum biomarkers. The real-time analytical capabilities of the technology 
streamlined the assay development and optimization process, and an automated layer-by-
layer signal enhancement scheme provided requisite analytical performance. Comparison 
of biomarkers levels across a narrow subset of samples suggest that panel-based disease 
“fingerprints” might have utility in the screening, early detection, or monitoring of disease 
on an individualized level. Obviously the next step for this technology involves the analysis 
of many more patient samples in concert with a more directed clinical applications and 
patient outcomes. However, we feel that this technological achievement is noteworthy in 
the context of analytical sensor development. Moreover, the cost effective and modularly 
multiplexable nature of the technology position it as an attractive platform for a wide 
number of biomarker-based diagnostic applications that are becoming increasingly 
valuable in the pursuit of personalized cancer diagnostics. 
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Figure 3.1 Photograph of silicon microchip overlaid with four red boxes indicating sub-
array regions containing 8 microring resonators, each functionalized with an antibody 
specific for a different cancer biomarker antigen. 
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Figure 3.2 8-plex analysis for cross reactivity and 8-plex serum sensing. a) Response of 8-
plex chip upon sequential addition of 1 µg/mL (or 1 kU/mL) of each antigen in buffer. Each 
plot shows the responses for the entire array of microring sensors, each functionalized with 
a different capture antibody, to a single biomarker. b) Response of the same 8-plex chip 
upon subsequent addition of 1 µg/mL of the capture antibody. Each plot shows the 
responses for the entire array exposed to the single listed analyte and corresponding tracer 
antibody. c) Schematic showing the layer-by-layer signal enhancement strategy. d) A real-
time plot showing the resonance wavelength shifts through the entire assay analysing a 
representative human serum sample. Vertical arrows represent the start of the primary, 
tracer, and secondary enhancement steps, respectively. The * symbol indicates a buffer 
rinse. For panels, a, b, and d, responses are color-coded according to the capture antibody 
on each microring: anti-AFP = black, anti-ALCAM = red, anti-CA19-9 = cyan, anti-
osteopontin = blue, anti-CA15-3 = purple, anti-CEA = orange, anti-CA125 = yellow, anti-
PSA = green. 
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Figure 3.3 Negative control experiment where 50% Starting Block solution is flowed across the 
array in the primary binding step. The running buffer before primary binding is 1% starting block 
in PBS-Tween 20 buffer (PBST), which explains the large bulk refractive index step. The 
experiment demonstrates that the tracer and secondary signal enhancement steps do not lead to 
non-specific binding responses. 
  
50 
 
 
Figure 3.4 Calibration curves for each cancer biomarker. Each plot shows the dose-response 
relationship and fit for each of the targeted antigens as detected by the specific sandwich assay 
immunoassay. Error bars were calculated based on the chip-to-chip variation of 17% CV, or ring-
to-ring standard deviation if larger than 17% CV. 
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Figure 3.5 Real-time response of the 8-plex cancer biomarkers assay in eight evaluated serum 
samples from healthy patients as well as cancer patients. Each panel shows the real-time shift in 
resonance shift throughout the entire assay to detect the 8-plex biomarker panel from each 
commercial, organ-specific serum sample. Although clear differences are observed through the 
primary antigen binding response, quantification is achieved only from the layer-by-layer 
secondary enhancement component of the assay. 
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Figure 3.6 Relative biomarker “fingerprints” for selected cancer patient serum samples. This 
“fingerprint” was generated by dividing the sensor response for each biomarker in each cancer 
serum sample by the response measured in the healthy serum sample. Error bars indicate the 
relative standard deviation for the four technical replicate sensors on each chip used to measure 
each antigen. A relative index level of 1.0 indicates (horizontal dashed lines in each plot) that the 
biomarker was equivalent in both disease and normal sample, with indices greater than 1.0 
representing organ-specific biomarker elevation. 
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Pancreas  Prostate  Liver Ovarian Breast Lung CRC  Healthy
ng/
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err
or 
ng/
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err
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err
or 
ng/
mL
 
err
or 
ng/
mL
 
err
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ng/
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err
or 
ng/
mL
 
err
or 
ng/
mL
 
err
or 
AFP  1.3  0.5  —  —  8.8 1.7 — — — — — — —  —  —  — 
ALCAM  >65  —  7.6  1.5  16.7 4.4 5.4 2.8 7.5 5.8 10.5 2.2  15.4  3.8  >65  — 
CA19‐9  >100  —  —  —  — — — — — — — — 3.8  2.0  —  — 
Osteopontin  14.6  2.1  —  —  21.3 3.3 6.1 0.7 — — 6.5 0.7  13.3  1.9  5.1  0.2 
CA15‐3  12.8  2.1  3.6  2.5  5.1  0.8  —  —  27.2  7.8  4.3  1.0  5.1  2.2  3.5  0.5 
CEA  >20  7.1  18.0  5.8  >20  12.5  3.9  2.1  12.0  3.4  19.9  6.8  >20  —  >20  — 
PSA  —  —  0.14  0.05  —  —  —  —  —  —  —  —  —  —  —  — 
 
Table 3.1 Measured concentration values for each serum sample. Entries with “>” indicate values 
are over the limits of quantitation; entries with “—” indicate values below the limits of 
quantitation. Bold values indicate the concentration and non-bold entries to the right represent the 
error of the measurement. 
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Antibody / Antigen Type  Source* Product Number Antibody Clone 
AFP 
Antigen  Meridian   A81510H
Capture  Meridian   MAM01‐301 057‐11301 
Detection  Meridian   M01254M B491M 
ALCAM 
Antigen  R&D Systems 656‐AL
Capture  R&D Systems MAB656  105901 
Detection  R&D Systems BAF656 Polyclonal 
CA 125 
Antigen  Fitzgerald 30‐AC21
Capture  Life Span LS‐C84288/ 28658 M002201 
Detection  Meridian   10‐C02F M002203 
CA 15‐3 
Antigen  Meridian   A32000H
Capture  Fitzgerald 10‐C03E M002204 
Detection  Fitzgerald 10‐C03F M002208 
CA 19‐9 
Antigen  Fitzgerald 30AC14
Capture  Fitzgerald 10C04C M8073021 
Detection  Meridian   M37301M 241 
CEA 
Antigen  Fitzgerald 30‐AC32
Capture  Meridian   MAM02‐009 057‐10009 
Detection  Meridian   MAM02‐008 057‐10008 
Osteopontin 
Antigen  Fitzgerald 30RA0008
Capture  Meridian   M66102M 2C5 
Detection  Meridian   H01278M B697M 
PSA 
Antigen  Fitzgerald 30R‐AP019
Capture  Meridian   M66279M B731M 
Detection  Meridian   M86506M 5A6 
*Full source information: 
Meridian Life Science, Saco, ME 
R&D Systems, Minneapolis, MN 
Fitzgerald Industries International, Concord, MA
Life Span Biosciences, Seattle WA
 
Table 3.2 List of antigens and antibodies used for eight-plex experiments, company source, 
product number and antibody clone (for monoclonal antibodies) 
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Name  Sequence (5′ to 3′) 
B  AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA 
B′  AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC 
C  AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA 
C′  AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC 
D  AAA AAA AAA AAT GGT CGA GAT GTC AGA GTA 
D′  AAA AAA AAA ATA CTC TGA CAT CTC GAC CAT 
F  AAA AAA AAA AAT CAG GTA AGG TTC ACG GTA 
F′  AAA AAA AAA ATA CCG TGA ACC TTA CCT GAT 
J  AAA AAA AAA ATC TTC TAG TTG TCG AGC AGG 
J′  AAA AAA AAA ACC TGC TCG ACA ACT AGA AGA 
K  AAA AAA AAA ATA ATC TAA TTC TGG TCG CGG 
K′  AAA AAA AAA ACC GCG ACC AGA ATT AGA TTA 
L  AAA AAA AAA AGT GAT TAA GTC TGC TTC GGC 
L′  AAA AAA AAA AGC CGA AGC AGA CTT AAT CAC 
M  AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT 
M′  AAA AAA AAA AAC AGG TTC AGA ATC CTC GAC 
 
Table 3.3 List of DNA oligonucleotide sequences used. All sequences have a 5′ terminal amino 
group attached via a 6-carbon chain (5AmMC6 from IDT) 
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Dose‐
Response 
Antigen 
# of 
Enhancement 
Steps 
A  B  C  D 
ALCAM  1  ‐45.85  66.50  2.85  0.046 
CA15‐3  6  ‐98.22  151.91  10.09  0.019 
CEA  1  ‐4214.83  25.29  ‐109.06  0.021 
PSA  2  ‐37051.34  165.89  ‐36.65  0.064 
             
Linear 
Antigen  Time Range (min)  Intercept  Slope 
 AFP  6  24.4  17.01 CA19‐9  6  15.2  1.91 
Osteopontin  4  ‐9.9  4.67 
CA125  6  7.4  1.07 
 
Table 3.4  Number of amplification steps used for the calibration curve, the upper and lower limits 
of quantitation used for these curves, and the fitting parameters for both the dose-response 
calibration curves as well as the linear calibration curves. 
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  MILLIPLEX® MAP Human 
Circulating Cancer Biomarker 
Magnetic Bead Panel‐ Cancer 
Multiplex Assay* 
8‐plex Microring Resonator Cancer 
biomarker assay 
  Working ranges 
AFP (ng/mL)  0.0747‐500  0.3‐20.6 
ALCAM  n/a  1.0‐43.7 
CA19‐9 (U/mL)  0.3‐625  2.5‐96.6 
Osteopontin (ng/mL)  0.2853‐500  4.3‐50.3 
CA15‐3 (U/mL)  0.03‐625  2.0‐91.5 
CEA (ng/mL)  0.0052‐500  0.2‐20.2 
CA‐125 (U/mL)  0.2‐625  2.4‐95.6 
PSA† (ng/mL)  0.0014‐500  0.054‐4.7 
* Working range was assumed to span from the Minimum detectable concentration up to the upper limit 
of the reported dynamic range, which may be an overestimate of the upper end of the working range. 
Values taken from MILLIPLEX® MAP Human Circulating Cancer Biomarker Magnetic Bead Panel 1 Protocol. 
† Reported free PSA value. 
Table 3.5 Comparison of working ranges for the MILLIPLEX® MAP Human Circulating Cancer 
Biomarker Magnetic Bead Panel and the 8-plex microring resonator cancer biomarker assay 
described in this manuscript. 
 
  
58 
 
3.6 References 
1. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, et al. Early detection: 
The case for early detection. Nature Reviews Cancer 2003;3:243. 
2. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of 
proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7. 
3. Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-52. 
4. Arnaud CH. Biomarkers wanted. Chemical and Engineering News 2011 July 25, 2011:40-
3. 
5. Rusling JF. Multiplexed electrochemical protein detection and translation to personalized 
cancer diagnostics. Analytical Chemistry 2013;85:5304-10. 
6. He B, Morrow TJ, Keating CD. Nanowire sensors for multiplexed detection of 
biomolecules. Current Opinion in Chemical Biology 2008;12:522-8. 
7. Carregal-Romero S, Caballero-Díaz E, Beqa L, Abdelmonem AM, Ochs M, Hühn D, et al. 
Multiplexed sensing and imaging with colloidal nano- and microparticles. Annual Review 
of Analytical Chemistry 2013;6:53-81. 
8. Muzyka K. Current trends in the development of the electrochemiluminescent 
immunosensors. Biosensors and Bioelectronics 2014;54:393-407. 
9. Estevez MC, Otte MA, Sepulveda B, Lechuga LM. Trends and challenges of refractometric 
nanoplasmonic biosensors: A review. Analytica Chimica Acta 2014;806:55-73. 
10. Luchansky MS, Bailey RC. Silicon photonic microring resonators for quantitative cytokine 
detection and t-cell secretion analysis. Analytical Chemistry 2010;82:1975-81. 
11. Washburn AL, Luchansky MS, Bowman AL, Bailey RC. Quantitative, label-free detection 
of five protein biomarkers using multiplexed arrays of silicon photonic microring 
resonators. Analytical Chemistry 2010;82:69-72. 
12. Foreman MR, Swaim JD, Vollmer F. Whispering gallery mode sensors. Adv Opt Photon 
2015;7:168-240. 
13. Washburn AL, Gomez J, Bailey RC. DNA-encoding to improve performance and allow 
parallel evaluation of the binding characteristics of multiple antibodies in a surface-bound 
immunoassay format. Analytical Chemistry 2011;83:3572-80. 
14. Bailey RC, Kwong GA, Radu CG, Witte ON, Heath JR. DNA-encoded antibody libraries: 
A unified platform for multiplexed cell sorting and detection of genes and proteins. J Am 
Chem Soc 2007;129:1959-67. 
15. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clinical Chemistry 
2002;48:1151-9. 
16. Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP. Activated 
leukocyte cell adhesion molecule: A novel biomarker for breast cancer. International 
Journal of Cancer 2009;125:9-14. 
17. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative 
levels of serum ca 19-9 correlate with improved survival for patients with resectable 
pancreatic adenocarcinoma. Annals of Surgical Oncology 2004;11:644-9. 
18. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al. Serum protein markers 
for early detection of ovarian cancer. Proceedings of the National Academy of Sciences of 
the United States of America 2005;102:7677-82. 
19. Schiemann U, Günther S, Gross M, Henke G, Müller-Koch Y, König A, et al. Preoperative 
serum levels of the carcinoembryonic antigen in hereditary non-polyposis colorectal cancer 
59 
 
compared to levels in sporadic colorectal cancer. Cancer Detection and Prevention 
2005;29:356-60. 
20. Szymendera J, Nowacki M, Szawlowski A, Kamińska J. Predictive value of plasma cea 
levels: Preoperative prognosis and postoperative monitoring of patients with colorectal 
carcinoma. Diseases of the Colon and Rectum 1982;25:46-52. 
21. Wang JY, Tang RP, Chiang JM. Value of carcinoembryonic antigen in the management of 
colorectal-cancer. Diseases of the Colon & Rectum 1994;37:272-7. 
22. Cao D-X, Li Z-J, Jiang X-O, Lum YL, Khin E, Lee NP, et al. Osteopontin as potential 
biomarker and therapeutic target in gastric and liver cancers. World Journal of 
Gastroenterology : WJG 2012;18:3923-30. 
23. Andriole GL, Crawford ED, Grubb RL, III, Buys SS, Chia D, Church TR, et al. Mortality 
results from a randomized prostate-cancer screening trial. New England Journal of 
Medicine 2009;360:1310-9. 
24. Rhea JM, Molinaro RJ. Cancer biomarkers: Surviving the journey from bench to bedside. 
MLO: Medical Laboratory Observer 2011;43:10-8. 
25. Luchansky MS, Washburn AL, McClellan MS, Bailey RC. Sensitive on-chip detection of 
a protein biomarker in human serum and plasma over an extended dynamic range using 
silicon photonic microring resonators and sub-micron beads. Lab on a Chip 2011;11:2042-
4. 
26. Luchansky MS, Washburn AL, Martin TA, Iqbal M, Gunn LC, Bailey RC. 
Characterization of the evanescent field profile and bound mass sensitivity of a label-free 
silicon photonic microring resonator biosensing platform. Biosensors and Bioelectronics 
2010;26:1283-91. 
27. Spaeth K, Brecht A, Gauglitz G. Studies on the biotin-avidin multilayer adsorption by 
spectroscopic ellipsometry. Journal of Colloid and Interface Science 1997;196:128-35. 
28. Anderson GP, Taitt CR. Suspension microarray immunoassay signal amplification using 
multilayer formation. Sensor Letters 2008;6:213-8. 
29. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early 
detection of prostate cancer: Aua guideline. The Journal of Urology;190:419-26. 
30. Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: How to order and interpret them. 
BMJ 2009;339. 
31. Iqbal M, Gleeson MA, Spaugh B, Tybor F, Gunn WG, Hochberg M, et al. Label-free 
biosensor arrays based on silicon ring resonators and high-speed optical scanning 
instrumentation. IEEE Journal of Selected Topics in Quantum Electronics 2010;16:654-
61. 
32. Fan R, Vermesh O, Srivastava A, Yen BKH, Qin L, Ahmad H, et al. Integrated barcode 
chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nature 
Biotechnology 2008;26:1373-8. 
 
60 
 
Chapter 4: 
Development and Validation of an Immunosensor for 
Monocyte Chemotactic Protein 1 using a Silicon Photonic 
Microring Resonator Biosensing Platform 
Acknowledgments 
This chapter was reproduced from “Development and validation of an immunosensor for 
monocyte chemotactic protein 1 using a silicon photonic microring resonator biosensing 
platform”. (Valera, E. V., Shia, W. W., Bailey, R. C. Clinical Biochemistry. 2016, 49, 121-126). 
This work is done in collaboration with Dr. Enrique Valera, especially for his efforts in 
data collection and putting together the final version of the manuscript. Prof. Ryan Bailey is 
acknowledged for initiating this project. 
We gratefully acknowledge financial support from the National Science Foundation 
(CHE 12-14081) and National Cancer Institute (R33-CA177462-01). WWS was supported by an 
American Heart Association Predoctoral Fellowship.   
61 
 
4.1 Abstract 
a) Objectives: 
We report the development of an optical immunosensor for the detection of monocyte 
chemotactic protein 1 (MCP-1) in serum samples. MCP-1 is a cytokine that is an emerging 
biomarker for several diseases/disorders, including ischemic cardiomyopathy, fibromyalgia, and 
some cancers.  
b) Design and Methods: 
The detection of MCP-1 was achieved by performing a sandwich immunoassay on a silicon 
photonic microring resonator sensor platform. The resonance wavelengths supported by 
microring sensors are responsive to local changes in the environment accompanying biomarker 
binding. This technology offers a modularly multiplexable approach to detecting analyte 
localization in an antibody-antigen complex at the sensor surface. 
c) Results: 
The immunosensor allowed the rapid detection of MCP-1 in buffer and spiked human serum 
samples. A 2.5 order of magnitude linear range was observed, between 84.3 and 1582.1 pg/mL 
and the limits of blank and detection were 0.3 and 0.5 pg/mL, respectively. The platform’s 
ability to analyze MCP-1 concentrations across a clinically-relevant concentration range was 
demonstrated. 
d) Conclusions: 
A silicon photonic immunosensor technology was applied to the detection of clinically-relevant 
concentrations of MCP-1. The performance of the sensor was robustly validated through a broad 
dynamic range and across a number of suggested clinical cut-off values. Importantly, the 
intrinsic scalability and rapidity of the technology makes it readily amenable to the simultaneous 
detection of multiplexed biomarker panels, which is particularly needed for the clinical 
realization of inflammatory diagnostics. 
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4.2 Introduction 
Major advances in the field of biomolecular detection have recently led to improvements 
in the sensitivity and specificity achievable for the detection of a myriad of biomarker targets. 
Many of these technologies have been applied to clinical diagnostics, where the analysis of 
biomarker signatures can be utilized to identify and monitor a wide spectrum of human diseases 
and disorders (1-5). Due to their important roles in modulating the immune response and 
inflammation, cytokines are attracting increasing attention for clinical diagnostics (6-8). 
Cytokines, a broadly defined category of small (~5–20 kDa) proteins that include chemokines, 
interleukins, interferons, lymphokines, and tumor necrosis factors, regulate many types of 
cellular interactions in response to both self- and non-self antigens. Not surprisingly, alterations 
of cytokine levels can be diagnostic for a wide variety of maladies, including autoimmune 
disorders, cancer, and pathogenic infections. Importantly, the low basal concentrations and 
overlapping functions of cytokines, coupled with the acute nature of many inflammatory 
conditions conspire to demand high analytical specifications for cytokine-based clinical 
diagnostics. To fully realize the promise of cytokine-based diagnostics, new technologies that 
deliver robust and cost effective performance with high sensitivity (pg/mL), specificity, and 
rapid time-to-result are needed. 
Of particular relevance to this manuscript is monocyte chemotactic protein 1 (MCP-1, 
also known as CCL2). MCP-1 is a low molecular weight (~13 kDa), 76-amino acid protein, that 
belongs to the CC chemokine family. MCP-1 is implicated in pathogeneses of several diseases 
such as ischemic cardiomyopathy (9), fibromyalgia syndrome (10), or systemic lupus 
erythematosus (11). It is also related to the rare neurological disorder Miller Fisher syndrome 
(12), and proposed as a biomarker for ovarian cancer (13). The concentrations of clinical interest 
of this cytokine vary considerably depending on its clinical application; however, studies have 
defined MCP-1 cut-off values of 130 pg/mL for fibromyalgia syndrome (10), 187 pg/mL in 
neonates with hypoxic-ischemic encephalopathy (14), and 718 pg/mL for prognosing ovarian 
cancer (13). 
As an alternative to plate- and bead-based immunoassays, our group has investigated a 
silicon photonic microring resonator technology that leverages robust and cost effective 
semiconductor fabrication techniques to create a sensitive and modularly multiplexable 
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biomolecular detection platform. Microring resonators are chip-integrated optical microcavities 
that support the propagation of optical modes that are extremely sensitive to the local refractive 
index environment. Specifically, photons of a particular wavelength will only propagate in the 
microring under a tightly held resonance condition. 
mλ = 2πrneff                                                     (1) 
In Equation 1, m is a non-zero integer, λ is the wavelength of light, r is the radius of the 
resonator, and neff is the effective refractive index sampled by the optical mode. Importantly, 
biomolecular binding events at the microring surface lead to a local change in refractive index, 
which in turn leads to a shift in the resonance wavelengths supported by the device. The shifts in 
particular resonance wavelengths can then be tracked for individual sensors and utilized to 
quantitate unknown amounts of biomolecular targets. Our group has previously demonstrated the 
applicability of this technology to detect a several different classes of biologically-relevant 
targets, including proteins, nucleic acids, viruses, and biotoxins (15-18). We have also 
demonstrated several different signal enhancement strategies on the silicon photonic platform 
(19-21) that deliver limits of detection comparable with many commercial immunoassays.  
In this manuscript we describe the development of a robust and high-performing silicon 
photonic immunosensor for MCP-1. Using an enzymatically-enhanced, sandwich immunoassay, 
we were able to sensitively detect this representative cytokine at sub-pg/mL levels with a 
relatively rapid (71 min) time-to-result. We demonstrate the ability to quantitate MCP-1 over a 
2.5 order of magnitude linear range in both buffer and human serum samples. We find minimal 
matrix effects when detecting in serum with full signal recovery achieved by a simple 10-fold 
dilution of the sample. Importantly, we demonstrate the ability to clearly detect MCP-1 
concentrations at the previously defined, clinically-relevant cut-off values for the biomarker. The 
robust performance metrics of this technology, coupled with the capability to perform 
multiplexed detection, position this technology as an attractive platform for inflammatory 
cytokine-based clinical diagnostics.  
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4.3 Materials and methods 
4.3.1 Instrumentation 
Resonance wavelength shifts were monitored using the Maverick Detection System 
(Genalyte, Inc., San Diego, CA). The pH of all buffers and solutions were measured with an 
Orion 3-star benchtop pH meter (Thermo Scientific). Data analysis was performed using 
OriginPro 9.1.0 (OriginLab Corporation, Northampton, MA) and calibration curves were fit with 
a four-parameter logistic equation using GraphPad Prism 5 for Windows (GraphPad Software, 
San Diego, CA). Data presented corresponds to the average of at least 16 on-chip technical 
replicates per concentration of MCP-1. 
4.3.2 Chemical and biochemical reagents 
Dulbecco’s phosphate buffered saline packets were purchased from Sigma-Aldrich (St. 
Louis, MO). 3-aminopropyltriethoxysilane (APTES) (cat. num. 80370), bis[sulfosuccinimidyl] 
suberate (BS3, cat. num. 21585), streptavidin-HRP conjugate (cat. num. 21130), 1-step 4-chloro-
1-naphthol (4-CN) solution, and StartingBlock (PBS) blocking buffer (cat. num. 37538) were 
purchased from Thermo Scientific. DryCoat assay stabilization reagent was purchased from 
Virusys (cat. num. AG066-1) and glycerol (cat. num. BP229-1) from Fisher BioReagents. The 
capture antibody (anti-Human MCP-1 (CCL2), cat. num. 14-7099), detection antibody 
(biotinylated anti-MCP-1 (CCL2), cat. num. 13-7096), and the target analyte (recombinant 
human protein MCP-1 (CCL2), cat. num. 14-8398) were purchased from eBioscience (San 
Diego, CA). The non-specific adsorption control antibody (Mouse IgG, cat. num. ab37355) was 
purchased from Abcam (Cambridge, MA). 
4.3.3 Buffers and solutions 
PBS buffer (10 mM) was reconstituted from Dulbecco’s phosphate buffered saline 
packets and the pH was adjusted to 7.4. The MCP-1 capture antibody was buffer exchanged to 
10 mM PBS, followed by addition of glycerol to a final 5% (v/v) glycerol in PBS. The assay 
running buffer was 0.5% BSA in 10 mM PBS. All buffer solutions were prepared with purified 
water (ELGA PURELAB filtration system; Lane End, UK). 
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4.3.4 Human serum samples 
Certified pooled normal human serum was obtained from Innovative research (Novi, MI). 
The test material was aliquotted upon receipt and stored at – 20C until to use. 
4.3.5 Silicon photonic microring resonators: Sensor substrates and read-out 
instrumentation 
The Maverick M1 optical scanning instrumentation utilized to measure shifts in 
microring resonance wavelengths and sensor substrates were obtained from Genalyte, Inc. The 
fabrication of the sensor chip and scanning instrumentation operation used has been described 
previously (22, 23). The 4 mm x 6 mm silicon-on-insulator chips each contain 128 individually-
addressable microrings. Four additional microrings rings in the fluidic channel, but covered by a 
fluoropolymer cladding layer, serve as controls to correct for thermal drift. An additional 4 
exposed microrings (no cladding layer) lie outside the fluidic channel and serve as leak sensors.  
Each individual microring is located next to an adjacent linear waveguide, such that 
interference between photons circulating the microring and passing down the linear waveguide 
create a resonant microcavity that supports optical modes only at specific wavelengths (23). The 
configuration of the fabricated chip allows for division of the 128 microrings in two fluidically-
addressable flow channels, as defined a laser cut Mylar gasket that is sandwiched between the 
chip and Teflon lid. This fluidic design allows two unique samples to be assayed simultaneously. 
To measure the resonance wavelength shift associated with the steps of the immunoassay, 
a tunable external cavity diode laser centered at 1550 nm serially probes each microring 
individually as a function of time. Resonances were determined as dips in the intensity of light 
propagating down the linear waveguide past the microring as the laser wavelength is scanned 
across a suitable spectral window. Relative shifts in resonance wavelength were recorded as a 
function of time during each of the immunoassay steps. The data acquisition software enables 
real-time control subtraction and averaging of active sensor responses. 
4.3.6 Surface functionalization 
Before functionalization, sensor chips were briefly rinsed with acetone to remove a 
protective photoresist coating. Sensor chips were immersed into a 5 % (v/v) solution of APTES 
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(2 mL in acetone, 4 min, with stirring) and then sequentially rinsed in acetone (2 min), 
isopropanol (2 min), and water. Silanized chips were gently dried under with N2, reacted with a 5 
mM solution of the BS3 crosslinker (20 μL, 2 mg in 700 μL 2 mM acetic acid) for 3 min, and 
again dried with N2.  
Solutions of capture and control antibodies (0.3 mg/mL, in 10 mM PBS with 5% glycerol) 
were immobilized onto specific regions in both channels of the chip via microspotting (0.2 μL 
per drop). Antibody solutions were reacted for 1 h at RT. The chips were then immersed in the 
blocking solution (600 μL, StartingBlock) for 1 h at RT. After blocking, the chips were dip-
coated with DryCoat (600 μL; 30 dips). After this procedure, the chips were stored in a 
desiccator at 4°C until use. 
4.3.7 Immunosensor measurement procedure 
Before each measurement, the chips were loaded into a base cartridge holder and then 
sandwiched between a 0.007” laser cut Mylar gasket, and a Teflon cartridge top. Solutions were 
delivered to the cartridge assembly via a 0.01” ID Teflon tubing screwed directly into the 
cartridge top. The reagents in the assay were diluted in degassed running buffer, and loaded into 
a 96-well plate. 
The Maverick system control software enables fully programmable reagent delivery. For all 
steps in the assay, the flow rate was 30 μL/min. Before starting the scan, the flow across the 
system was checked by a pre-buffer rinse step (< 4 min, running buffer). Solutions were flowed 
across both channels of the chip in the following order: 1) running buffer (2 min); 2) sample (20 
min); 3) running buffer (2 min); 4) biotinylated detection antibody (10 min, 4 μg/mL); 5) running 
buffer (2 min); 6) streptavidin-HRP conjugate (10 min, 4 μg/mL); 7) running buffer (3 min); 8) 
4-CN (15 min, 4 μg/mL); 9) running buffer (7 min). The total assay time was 71 minutes. 
4.3.8 Data analysis and processing 
The resonance wavelength shifts, related to the MCP-1 concentration, were calculated using 
the OriginPro 9.1.0 software, after subtracting responses from thermal and leak rings. Standard 
curves were constructed using GraphPad Prism 5 for Windows by plotting the resonance shift as 
a function of MCP-1 concentration and fitting to a logistic four-parameter equation: 
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Y = (A − B) / [1 + (x/C)D] + B 
where A is the shift measured for the highest concentration of target, B is the shift measured for 
the lowest concentration of target, C is the concentration producing 50% of the maximum 
response, and D is the slope at the inflection point of the sigmoid curve. The limit of blank (LoB) 
was estimated as the concentration providing the average of the blank plus 3 time the standard 
deviation of the blank. The limit of detection (LoD) was defined as the lowest value that has a 
95% confidence to exceed the LoB (24). Thus, the LoD was estimated as: 
LoB + (cβ x SDS) 
where SDS is the analytical standard deviation of a sample with the lowest measured 
concentration (0.2 pg/mL), and cβ is the standard normal deviate (approximately 1.65). The 
working range was determined to be in the interval between 20% and 80% of the A value. 
4.4 Results 
The objective of this work was to robustly validate the ability of the silicon photonic 
microring resonator platform to measure MCP-1 in buffer and human serum samples, and to 
establish quantitative detection metrics. The sensor array was first created by covalently 
immobilizing capture and control antibodies onto discrete sensor elements (Figure. 4.1a). Chips 
were assembled into a fluidic cartridge (Figure. 4.1b) and loaded into the Maverick detection 
system for analysis. 
A pair of commercial antibodies against MCP-1 (capture and detection) was identified 
and utilized in a sandwich immunoassay, each step of which was monitored in real time using 
the silicon photonic detection platform (Figure. 4.1c). After functionalization and establishing 
baseline in running buffer (t = 0 min, and between subsequent reagent steps throughout assay), 
standard solutions of MCP-1 (between 0 and 50000 pg/mL, prepared in running buffer) were 
flowed across the chip surface (t = 2 min). Biotinylated detection antibodies were then 
introduced (t = 24 min), followed by a streptavidin−HRP conjugate (t = 36 min). The 4-CN 
solution was then introduced (t = 49 min) and the catalytic conversion of 4-CN to the insoluble 
4-CNP was measured by subtracting the net resonance wavelength shift from running buffer 
steps immediately before and after the 4-CN/4-CNP step. The magnitude of resonance 
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wavelength shift from the 4-CNP step was related to the concentration of MCP-1 concentration 
in each standard solution. 
The shift in resonance wavelength observed for different concentrations of MCP-1 is 
shown in Figure. 4.2a. This same data is plotted as a dose-response curve in Figure. 4.2b (for 
detailed values see Table 4.1), and from this data the LoB and LoD were determined to be 0.3 
and 0.5 pg/mL, respectively, and the linear range of the assay was between 84 and 1582 pg/mL. 
Responses for microrings functionalized with a control antibody were negligible. 
Turning to the analysis of human serum samples, the effects of the sample matrix on 
sensor response was determined. To accomplish this, pooled human serum samples were spiked 
with a high concentration of MCP-1 (10000 pg/mL). At this concentration the response is very 
near the saturated region of the calibration curve, meaning that any small amount of MCP-1 
natively present in the human sample would not significantly change the sensor response. This 
allows for the direct observation of matrix effects. Figure. 4.2c shows the observed resonance 
wavelength shifts recorded under different dilutions of the spiked serum sample, when compared 
to equivalent concentrations measured in running buffer, after correction for dilution. A 1:1 
dilution showed a ~15% reduction in response. A 1:5 dilution reduced this matrix effect and a 
1:10 dilution showed full response recovery. Further dilution (1:20) did not improve the response 
recovery. 
Working at this optimized 1:10 dilution, we analyzed human serum samples spiked with 
concentrations of MCP-1 surrounding clinically-established cut-off values associated with 
specific diseases/disorders. Specifically, cut-offs at 130 and 710 pg/mL have been established for 
fibromyalgia syndrome (10) and ovarian cancer (13), respectively. After 1:10 dilution, serum 
samples were spiked with 13, 30, 71.8 and 100 pg/mL of MCP-1. A non-spiked serum sample 
was used as reference. The measured resonance wavelength shifts for each of the spiked samples 
(n ≥ 23 microring sensors for each sample) were interpolated to the buffer calibration curve, and 
the resulting MCP-1 concentrations determined are plotted in Figure. 4.3. The good agreement 
between the spiked values and those determined using the microring resonator technology is 
numerically illustrated in Table 4.2. Both of these representations illustrate that the microring 
immunosensor is capable robustly quantitating the concentration of MCP-1 in human serum 
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samples. This analysis also allowed determination of the concentration of MCP-1 natively 
present in the serum sample to be 56 ± 16 pg/mL. 
4.5 Discussion 
Silicon photonic microring resonators are an emerging optical sensing technology that is 
attractive for biomolecular diagnostic applications. This refractive-index sensitive technology 
can be operated in a label-free mode wherein the biomolecular target of interest does not have to 
be covalently modified with any chromogenic, fluorescent, or enzymatic tag. However, the use 
of multiple, high affinity, target-specific recognition elements (i.e. monoclonal antibodies) 
allows this technology to be deployed for the quantification of disease-relevant biomarkers 
within clinically-relevant matrices. In this manuscript, we utilize arrays of silicon photonic 
microring resonators in a sandwich immunoassay format for the detection of MCP-1, an 
inflammatory cytokine associated with a number of clinically-relevant diseases/disorders, 
robustly validate the sensor performance, and demonstrate many important analytical parameters. 
The natively passivated silicon oxide present on the resonators makes it amenable to 
standard silane chemistries and bioconjugate techniques, analogous to those used in many 
conventional microrarrays. The sensors were first covalently modified with a monoclonal 
antibody specific for MCP-1. Importantly, the small size of the sensor minimizes reagent 
consumption such that < 1 μL (0.3 mg/mL) was needed to achieve a large number (n ≥ 23) of 
technical replicates on a single chip. After functionalization, MCP-1 standards or human serum 
samples were flowed across the antibody-functionalized sensor array. To ensure assay specificity 
within complex matrices, a biotinylated, monoclonal anti-MCP-1 monoclonal antibody targeting 
a different epitope was introduced as a tracer antibody. Though the resonance wavelength shift 
accompanying the binding of the tracer antibody is observable above the noise baseline at many 
concentrations, the signal can be greatly increased through an enzymatic enhancement step. 
Specifically, a streptavidin-HRP conjugate that recognizes the surface-localized, biotinylated 
tracer antibody is introduced. This enzyme can then catalytically convert a soluble 4-CN reagent 
into an insoluble 4-CNP product that is physically deposited on the microring surface (21), with 
the amount of precipitate  
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For the detection of MCP-1 on the silicon photonic microring resonator platform, the 
entire sandwich immunoassay took a total of 71 minutes and each step was monitored in real-
time, as shown in Figure. 4.1c and Figure. 4.2a. By comparison, commercially available ELISA 
kits do not allow real-time visualization of each step and typically require much longer assays 
(R&D systems, 3.5 or 4.5 h (25); Thermo Scientific, 3h (26). The ability to watch each assay step 
in real time permits the observation of gross failures that might otherwise not be revealed until 
the final stage of assay read-out. The resonance wavelength shift from this final enzymatic 
enhancement step is measured and utilized to generate a standard curve and quantitate unknown 
levels of MCP-1 (Figure. 4.2b). Statistical analysis of the standard curve yielded LoD and LoB 
values of 0.5 and 0.3 pg/mL, respectively, and highlighted a broad 2.5-order of magnitude 
dynamic range up to ~1600 pg/mL (Table 4.1). Across this dynamic range, CVs were generally ≤ 
10%. Importantly, these values compare well with both plate- and bead-based commercial assays 
for MCP-1,(25-27) which report sensitivities ranging from 0.47 - 10 pg/mL, similar working 
ranges, and CVs. Importantly, by requiring just over 1 h the microring immunosensor is 
considerably more rapid than these commercial immunoassays. Additionally, while not the focus 
of this report, antibodies specific for multiple targets can be simultaneously arrayed onto 
different microring sensor elements on a single chip allowing for high levels of multiplexing, 
similar to Luminex.(27) Therefore, the simultaneous quantitative analysis of multiple 
cytokine/chemokines should be readily achievable using the microring detection technology. 
Essential to any clinically-relevant assay is the ability to assess and compensate for any 
matrix effects. To probe these effects, we spiked a known concentration of MCP-1 into human 
serum samples and found that only minor signal attenuation was observed (Figure. 4.2c) and that 
full response recovery could be achieved with only a 1:10 dilution of the serum samples into 
running buffer. Using this dilution, we then validated the ability to detect MCP-1 from within 
spiked serum at concentrations that corresponded to clinically-relevant cut-off values suggested 
for both fibromyalgia syndrome and ovarian cancer. The silicon photonic immunosensor was 
clearly able to distinguish baseline serum levels from these cut-off values with the measured 
shifts in resonance wavelength being quantitative through extrapolation to the standard 
calibration curve and with good response recovery through the linear working range (Table 4.2). 
Values for the lower spiked concentrations showed a reduced percent recovery; however, the 
absolute values are within 15 pg/mL of the spiked concentration. 
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Beyond the scope of this manuscript, it is worthwhile to mention that the current 
generation sensor chip has the capacity to be functionalized with up to 32 target-specific capture 
antibodies, which in principle would allow for high levels of multiplexing. Coupled with the 
rapidity and robust analytical performance metrics, we feel that this silicon photonic detection 
platform could be a valuable tool for translational applications of multiplexed cytokine and other 
biomarker-based diagnostics. 
4.6 Conclusions 
A silicon photonic immunosensor technology was applied to the detection of clinically-
relevant concentrations of MCP-1. The performance of the sensor was robustly validated through 
a broad dynamic range and across a number of suggested clinical cut-off values. Performance 
metrics were comparable to commercial ELISA assays for this biomarker; however, the silicon 
photonic immunoassay was considerably more rapid. Importantly, the intrinsic scalability of the 
technology makes it readily amenable to the simultaneous detection of multiplexed biomarker 
panels, which is particularly needed for the clinical realization of inflammatory marker-based 
diagnostics. 
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Figure 4.1 a) Schematic representation of the microring arrays on the sensor chip and the 
distribution of immobilized antibodies on chip. The antibodies were spotted in an identical 
formal over the two channels; b) Image of a chip assembled inside of the fluidic cartridge used; 
c) Overall strategy for the HRP-enhanced detection of MCP-1. MCP-1 concentration = 50000 
pg/mL (buffer). 
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Figure 4.2 a) Data recorded with the developed immunosensor. MCP-1 standard solutions 
prepared in running buffer; b) Representative calibration curve (black curve, running buffer). See 
Table 4.1 for details. Each data point shown corresponds with the average of at least 23 
replicates. The red curve corresponds to the signal of the control antibody; c) Matrix effect of 
pooled human serum. 
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Figure 4.3 Concentrations around MCP-1 cut-offs values, 10-fold, were spiked (13, 30, 71.8 and 
100 pg/mL) to the 10 times diluted serum samples. The signal obtained was converted to a MCP-
1 concentration via the buffer calibration curve. Inset: correlation between the spiked samples 
and the measured values by the developed immunosensor. The error bars corresponded to the 
standard deviation of n≥23 replicated microring sensors measurements. The non-spike serum 
sample was used as reference. 
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  MCP‐1 Immunosensor * 
Signalmin  53.9 pm 
Signalmax  7833 pm 
Slope  0.79 
LoB  0.3 pg/mL 
LoD  0.5 pg/mL 
Working range 84 – 1582 pg/mL 
R2   0.998 
 
*  S/N = 145.  The  standards were measured with  the  immunosensor  following  the procedure 
described in the experimental section. The parameters were extracted from the four‐parameter 
equation used to fit the standard curve. 
 
Table 4.1 Detailed values of the MCP-1 immunosensor calibration curve in running buffer 
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Human Serum Samples (1/10 dilution) * 
Spiked concentrations  
(pg/mL) 
Measured concentrations 
(pg/mL) 
Recovery 
(%) 
RSD  
(%) 
13  5 ± 4  41  28 
30  16 ± 5  52  16 
71.8  68 ± 7  94  10 
100  91 ± 17  91  17 
 
* The non‐spike serum sample was used as reference. 
The  parameters  were  extracted  from  the  four‐parameter  equation  used  to  fit  the  standard 
curve. 
 
Table 4.2 Analysis of spiked human serum samples using the MCP-1 immunosensor. The 
reported concentrations were calculated based on the average of interpolated concentrations from 
n≥23 replicated measured microring response based on the calibration curve of the assay, along 
with the associated standard deviation of each interpolated concentration. 
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Chapter 5: 
A Silicon Photonic Immunoassay for Cardiac Troponin I 
using a Microring Resonator Biosensing Platform 
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5.1 Abstract 
Cardiac troponins are highly selective markers for myocardial injury and therefore troponin 
assays hold potential for monitoring a broad spectrum of cardiovascular disorders, allowing timely 
intervention to improve patient outcome. Currently, there is a need for simultaneously rapid and 
sensitive troponin assays that could be used in in emergency care settings. An automated 54 minute 
cardiac troponin I (cTnI) sandwich immunoassay was developed on a microring resonator analysis 
platform. Serum matrix effects were evaluated for influences on assay sensitivity and selectivity. 
After assay optimization, cTnI levels from 11 cardiac disease patient serum samples were 
quantified and showed good correlation with values obtained using the Siemens ADVIA Centaur 
XP-TnI platform. This work describes initial efforts to apply a novel and highly automated silicon 
photonic detection technology to the detection of cardiac troponin. While further assay 
optimization will be required to lower the limit of detection, the good quantitative correlation with 
a standard laboratory-based assay demonstrates the potential of microring resonators for the 
measurement of clinically-relevant biomarkers.  
5.2 Introduction 
Cardiovascular diseases (CVDs) are the leading cause of death globally, claiming an 
estimated 17.5 million lives in 2012.(1) Reliable biomarkers that can differentially diagnose 
between acute and chronic cardiovascular diseases offer a powerful opportunity to make timely 
diagnoses and implement the most effective personalized treatments. Among the numerous 
biomarkers proposed for CVDs, cardiac troponins, and specifically the subunits I (cTnI) and T 
(cTnT), have nearly perfect specificity for myocardial injury. They also remain elevated in the 
blood stream for a longer time period compared with other cardiac biomarkers and are considered 
as gold standard markers to diagnose acute myocardial infarction (AMI).(2-4) Elevation of 
troponins levels continues to increase within an hour after the onset of cardiac injury, reaching 
peak levels (~100 ng/ml) at 16-32 hrs before degrading over the next 5-7 days.(5, 6) Technologies 
amenable to early and longitudinal monitoring of troponin levels would be a powerful tool in 
assessing patient status during acute cardiovascular events. 
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There currently is an unmet need for simultaneously rapid and highly sensitive troponin 
assays. Laboratory-based troponin assays have exceptional detection limits but have relatively 
long assay times that include transport to a central lab facility, whereas point-of-care assays can 
be conducted rapidly in emergency room settings but lack the analytical performance to monitor 
low enough levels to be clinically actionable on their own.(7-9) 
Silicon photonic microring resonators are an emerging biomolecular detection technology 
that features attributes that may be useful for the detection of cardiac troponins. Specifically, 
relatively rapid and highly automated assays have been reported with limits of detection that reach 
levels of clinical utility.(10-13) Moreover, the robust fabrication of these silicon microdevices and 
integration with microfluidic fluid handling are well-suited for detection at the point-of-care. We 
have previously described the basic operation of these devices, as well as instrumentation 
developed to rapidly perform these measurements.(14, 15) Applied to biomarkers of potential 
clinical interest, we have demonstrated the ability to detect a number of inflammatory biomarkers, 
including C-reactive protein and cytokines,(10-12) as well as perform a multiplexed assay for 
phosphoproteins from tumor homogenate.(13) The detection of C-reactive protein is notable in the 
context of cardiovascular function as it has been speculated to play both and problematic roles in 
cardiovascular function, depending on the underlying pathophysiology.(16) 
Herein, we report the application of this silicon photonic detection platform to cardiac 
troponin I. An antibody-based sandwich assay was developed and utilized for replicated analysis 
of 11 patient serum samples, with determined levels correlating well with those obtained using the 
commercial Siemens ADVIA Centaur XP-TnI system. While many improvements are still needed, 
this demonstration helps illustrate the future potential for this technology in the portfolio of clinical 
diagnostic tools.  
5.3 Materials and methods 
5.3.1 Reagents and buffers 
Zeba Spin desalting columns (Cat. 89882), EZ-link NHS-PEG4-Biotin (Cat.21329), 3-
aminopropyltriethoxysilane (APTES, Cat. 80370), bis(sulfosuccinimidyl)suberate (BS3, Cat. 
21585), 1-step chloronaphthol solution (1-step CN, Cat. 34012), StartingBlock blocking buffer 
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(Cat. 37538), glycerol (Cat. BP2291) and high sensitivity streptavidin-horseradish peroxidase 
conjugate (SA-HRP, Cat. 21130) were purchased from Thermo Fisher Scientific (Rockford, IL). 
DryCoat assay stabilizer (Cat. AG066-1) was from Virusys (Taneytown, MD). Nunc Maxisorp 
flat-bottom 96 well plates were purchased from eBioscience (San Diego, CA). Mouse IgG isotype 
control antibody (Cat. Ab37355) was purchased from Abcam (Cambridge, MA). Pooled normal 
human serum (Cat. IPLA-SER) was purchased from Innovative Research (Novi, MI). Monoclonal 
mouse anti-cardiac troponin I capture (Clones: M18, 560) and tracer (Clones 19C7, MF4) 
antibodies 2(Cat. 4T21), and human cardiac troponin ITC complex (Cat. 8T62) were purchased 
from HyTest (Turku, Finland). All other reagents were purchased from Sigma-Aldrich (St. Louis, 
MO). 
A 10 mM PBS buffer was prepared by dissolving Dulbecco’s phosphate buffered saline 
powder to distilled water, adjusted to pH 7.4 and filtered. The assay running buffer was prepared 
by dissolving 0.5% (w/v) BSA into 10 mM PBS.  
5.3.2 Patient samples 
Serum samples from patients admitted with acute cardiovascular disease and elevated 
values of cardiac troponin T were previously obtained and stored at -80 °C at Mayo Clinic 
(Rochester, MN). These samples were collected under consent according to an IRB-approved 
protocol during standard clinical treatment at the Emergency Department at Mayo Clinic and 
supplied to researchers at the University of Illinois in a de-identified format. 
5.3.3 Biotinylation of tracer antibodies 
cTnI tracer antibodies (Clones 19C7 and MF4, specific to residues 41-49 and 190-196 
respectively) were first buffer exchanged to PBS buffer to remove sodium azide. NHS-PEG4-
Biotin (20 mM) was then added to each antibody in 20× molar excess and allowed to react at room 
temperature for 30 min. Excess biotinylation reagent was removed by spin filtration. The two cTnI 
tracer antibodies were then combined and diluted to 2 µg/ml final concentration of each antibody. 
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5.3.4 Surface chemistry, and spotting of capture antibodies 
Similar to the tracer antibodies, the mouse IgG control and cTnI capture antibodies (Clones 
M18 and 560, specific to residues 18-28 and 83-93 resprctively) were buffer exchanged to remove 
sodium azide. Glycerol was then added and antibodies diluted to a concentration of 1 mg/ml in 5% 
(v/v) glycerol. The capture antibodies were combined together with each antibody clone having a 
final concentration of 0.5 mg/ml in 5% (v/v) glycerol in preparation for spotting on the sensor 
chips surface. 
Microring resonator sensor chips were cleaned in piranha solution (3:1 H2SO4/30% H2O2, 
10 s), followed by generous rinsing in distilled water and dried under N2 (Caution! Piranha 
solutions are extremely dangerous and react explosively with organics.). The chips were immersed 
in acetone (2 min), 5% (v/v) APTES (in acetone, 4 min), fresh acetone (2 min), isopropanol (2 
min), and rinsed distilled water (2 min), with gentle swirling during each step. After drying under 
N2, a 5 mM BS3 linkers (20 µL, dissolved in 2 mM acetic acid) was spotted on the silanized chip 
surface to react with the free amine groups for 3 min. The linker solution was then removed and 
the capture and control antibodies were manually spotted, and allowed to incubate for 1 h. Chips 
were then immersed for 1 h in StartingBlock before a final rinse in DryCoat solution. Spotted chips 
were stored in a desiccator at 4°C until use. 
5.3.5 Silicon photonic microring resonators instrumentation 
Microring resonator sensor chips and Maverick optical scanning instrument were designed 
in collaboration with and acquired from Genalyte (San Diego, CA), as has been previously 
described.(17) Briefly, silicon photonic microring resonators support optical resonances at discrete 
wavelengths as described by: 
݉ߣ ൌ 2ߨݎ݊௘௙௙ 
where m is an integer, λ is the wavelength of light, r is the microring radius, and neff is the refractive 
index of the local ring environment. Microrings can be modified with target-specific capture agents 
(e.g. antibodies) and analyte binding events at the sensor surface cause a change in the local 
refractive index, which in turn leads to a shift in the resonance wavelength (), which is measured 
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in units of picometers (pm).  The latest chip design includes an increase to a total of 128 active 
microring sensors on a 4 × 6 mm chip footprint. The latest instrumentation also features complete 
automation of fluid handling, via robotic sipping form 96- or 384-well plates.  
5.3.6 Chip loading and assay details 
Sensor chips pre-immobilized with capture and control antibodies were placed on to an 
aluminum chip holder, aligned to a 2-channel Mylar fluidic gasket and sandwiched against a 
Teflon lid that allowed connection of inlet and outlet tubing to direct assay reagent flow over the 
two active channels on the chip, before loading into the Maverick M1 system. Separately, assay 
reagents were loaded into a 96-well plate, also placed within the instrument. The instrument was 
then programmed to record resonance wavelength shifts while running the following pre-defined 
assay steps when optimizing the assay in 0.5% BSA running buffer: (1) Running buffer (3 min). 
(2) Introduction of sample/ITC calibrator solutions (15 min, samples 50% diluted in running 
buffer). (3) Rinse with running buffer (1 min). (4) Introduction of biotinylated tracer antibodies (4 
min, 2 µg/mL each of clones 19C7 and MF4). (5) Running buffer rinse (1 min). (6) Introduction 
of SA-HRP solution (4 min, 4 µg/mL). (7) Running buffer rinse (2 min). (8) Introduction of 1-step 
CN (9 min). (9) Final running buffer rinse (3 min). The flow rate for all assay steps was set at 30 
µL/min, except for analyte introduction (2), which was at 10 µL/min. The total time for this assay 
in buffer was 42 min. Later on when the assay was further optimized to test serum matrices, the 
steps of introducing tracer antibodies and SA-HRP were both increased to 10 min, thus increasing 
the total assay time to 54 min. The 1-step CN solution contains a stabilized mixture of 4-chloro-1-
naphthol and H2O2, which in the presence of HRP, is converted to 4-chloro-1-naphthon—a 
precipitate that deposits on the microring surface giving a large signal enhancement. 
5.3.7 Normalization of assay response in patients’ serum samples 
In order to account for daily fluctuations in assay response, two samples of 50% diluted 
pooled serum, one spiked with 625 µg/L troponin ITC (highest concentration in the assay 
calibration curve in Figure 3), and the other remaining un-spiked (0 µg/L ITC), were also measured 
on the same day of patients’ samples measurements. The measured response of these two samples 
were set to 100% and 0% of the calibration curve response respectively, and assay response from 
each patient sample was re-expressed as a percentage response of the calibration curve for 
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normalization across the different days of measurements. In general, these correction factors were 
extremely minor; however, included as a precaution. 
5.3.8 Data analysis 
The net shifts in resonance wavelength were determined only before and after the 1-step 
CN signal enhancement. This avoid recording signal from non-specific adsorption that occurs in 
the presence of complex sample matrices. Specifically, the resonance shift at 43 min (Prior to 
addition of 1-step CN) was subtracted from that at 54 min (during buffer rinse). This response 
difference was normalized using the thermal control rings to correct for fluctuations in temperature 
during the assay run. Calibration plots obtained from the net shifts values on the microrings, as 
well as interpolation of serum sample responses, were analyzed using both OriginPro software and 
GraphPad Prism 5. The calibration plot was fitted by the following dose response equation: 
ݕ ൌ ܣ1 ൅ ܣ2 െ ܣ11 ൅ 10ሺ୪୭୥௫଴ି௫ሻ௣ 
Where A1 is the bottom asymptote, A2 is the upper asymptote, x0 is the concentration at half 
response (EC50), and p is the hill slope of the fitted plot. The limit of blank (LOB) for described 
assays was defined as the interpolated concentrations generated by the mean blank measurement 
signal plus 1.645 standard deviations (1.645σ) of that measurement, based on the CLSI 
recommendations reported by Linnet et. al.(18) Similarly, the limit of detection (LOD) was 
calculated as follows: 
ܮܱܦ ൌ ܮܱܤ ൅ 1.645ߪ 
The working range was determined to be the analyte concentrations that generate instrumental 
response in the interval between 20% and 80% (EC20 to EC80) of the A2 value, which corresponds 
to the linear range of the calibration curve. 
5.4 Results 
Anti-cTnI capture and mouse IgG control antibodies were spotted in an identical layout for 
both channels on the microring array sensor chips (Figure 5.1a) allowing for two samples to be 
tested simultaneously. For the quantitative detection of cTnI, an enzymatically-enhanced sandwich 
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immunoassay was utilized (Figure 5.1b), which was previously utilized on this platform to achieve 
LODs for interleukins IL-2, IL-6, and IL-8 at and below the pg/mL level.(19) Standard solutions 
or patient samples flowed across the array allowing the binding of cTnI to the target-specific 
capture agents. Biotinylated anti-cTnI tracer antibodies were then flowed across the array, 
specifically binding to the analyte captured by the primary antibodies. Streptavidin-HRP conjugate 
was then introduced followed by the enzymatic enhancement using the 1-step CN reagent. The 
cTnI assay was optimized by spiking various concentrations of human troponin ITC complex into 
running buffer and observing the real-time shifts in resonance wavelength during the assay steps 
(Figure 5.2a). The resulting resonance shifts measured from the CN enhancement step (between 
29 min and 40 min of the assay) were recorded and plotted as a function of cTnI concentration to 
obtain a calibration curve (Figure 5.2b). Responses were also recorded from IgG isotype control 
sensors, revealing minimal non-specific binding response. Table 5.1 summarizes the key analytical 
parameters, including a LOB and LOD for the assay in buffer of 0.010 ng/ml and 0.015 ng/ml, 
respectively, and working range of 0.5-9.4 ng/ml.  
 Moving to analyses in serum, the troponin ITC standard was spiked into 50% and 33% 
diluted serum. An initial analysis at 125 ng/ml of troponin ITC in these two matrices, compared to 
the assay performed in running buffer, showed a response reduction of ~1000 pm (Figure 5.3 
Inset). This matrix effect was not reduced with further dilution and therefore 50% diluted serum 
was selected for further assay evaluation. Using diluted serum samples spiked with a range of 
troponin concentrations, a calibration curve was constructed (Figure 5.3). Table 5.2 summarizes 
key analytical parameters for the assay performed in 50% diluted serum, including a LOB and 
LOD of 0.001 ng/ml and 0.003 ng/ml, respectively, and working range of 1.9-179.5 ng/ml.  
 This sandwich immunoassay on the silicon photonic platform was then applied to the 
measurement of troponin levels from 11 patient samples (Patients A-K). Each blinded serum 
sample was diluted 50% prior to measurement and the resulting resonance shifts converted to a 
troponin concentration using the serum calibration described above. Since these measurements 
were performed on different days from the calibration curve, daily fluctuations in assay response 
were normalized as described in the Materials and Methods section. Eight of the samples had 
detectable troponin levels, while three yielded responses lower than the LOD of the assay. For 
comparison with a validated clinical assay, the same patient samples were also evaluated using the 
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Siemens ADVIA Centaur XP-TnI assay at Mayo Clinic. However, troponin concentrations from 
the Siemens assay gave consistently higher values compared with those obtained from the 
microring assay (Figure 5.4a). Interestingly, plotting the Siemens versus microring troponin levels 
(Figure 5.4b) showed a strong correlation (R2=0.952) with a positive slope (m=3.40), which 
suggested a possible discrepancy between the calibrators used in the two assays. A series of 
troponin ITC standards used for the microring calibration were prepared in 50% serum and 
submitted for analysis on the Siemens assay platform and similar correlation was observed (Figure 
5.5; R2=0.995, m=3.16). Given the apparent inconsistency between the as prepared troponin 
standard values and the Siemens results, the microring resonator serum calibration curve was 
replotted using the Siemens cTnI concentrations as x-axis values. Using this corrected microring 
calibration, serum troponin values were re-evaluated and found to be in good agreement with those 
measured on the Siemens platform (Figure 5.6). Additionally, the three serum samples with 
undetectable troponin levels on the microring array platform (Patients I-K) were found via Siemens 
to have cTnI values ≤1 ng/ml. Considering this and the lowest quantitated patient sample (Patient 
H), the lowest detectable concentration for the microring assay was empirically estimated to be 2 
ng/ml. 
5.5 Discussion 
The goal of this work was to develop a silicon photonic immunosensor for cardiac troponin 
using a recently developed microring resonator detection technology. This technology is attractive 
on account of its relatively rapid and cost effective analytical capabilities. As a target for assay 
development and validation, we utilized a commercially available troponin ITC complex, rather 
than the cTnI subunit alone. Importantly, the selection of standard calibrator materials and the 
impact on assay performance has been a point of considerable discussion.(20, 21) With 
consideration of literature precedent, the HyTest ITC standard was selected as it demonstrated 
consistent analytic response.(21-23) Capture and detection antibodies were also selected to target 
epitopes at the stable midfragment region and terminal ends of the cTnI subunit, in hopes to reduce 
interferences from troponin autoantibodies.(24, 25) 
The immunoassay was developed first in buffer (Figure 5.2) and then in 50% diluted serum 
(Figure 5.3). When evaluating patient samples and comparing the microring immunoassay against 
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the Siemens ADVIA Centaur XP-TnI platform, the measured troponin values were correlated, but 
offset a factor of ~3.4, with the Siemens values being uniformly higher (Figure 5.4). Concerned 
that differences in the calibration standard might explain this discrepancy, a series of HyTest ITC 
complex standards used for microring measurements was analyzed on the Siemens platform and 
found to again give values ~3.2 times larger than the as prepared ITC concentrations (Figure 5.5). 
Having confirmed that the assay discrepancies could be corrected taking into account the offset in 
measured versus as prepared calibrator concentrations, the microring calibration curve was 
corrected and replotted using the Siemens cTnI values as the standard concentrations on the x-
axis. Re-evaluating the patient samples with the corrected microring calibration curve, good 
agreement was found between the silicon photonic and Siemens measurement platforms (Figure 
5.6). Notably, microring resonator measurements utilized an array of sensors that offered at least 
10 technical replicates per analysis, allowing confidence intervals to be determined on the basis of 
technical assay variation. Historically, cTnI assays have been plagued by high assay-to-assay 
variation (21, 23, 26, 27), and therefore the correlation for this first generation silicon photonic 
assay with the Siemens platform is encouraging. 
A sandwich immunoassay was developed and applied to the detection of troponin in patient 
serum samples, showing reasonably good correlation with an established clinical assay after 
calibrator normalization. While improvements remain to be achieved for the detection of cTnI on 
the silicon photonic platform—most notably in a need for a lower limit of detection—this initial 
demonstration is promising. Two potential routes to lower limits of detection include the selection 
of higher affinity capture agents and the integration of an on-chip sample pre-concentration 
module. This assay adheres  within the ACC/AHA target of <1 hr,(28) with added advantage in 
the ability to perform multiplexed measurements.(11, 13, 29, 30) In this report, the array of 
microrings was functionalized only with anti-cTnI and isotype control antibodies; however, this 
array could also be functionalized with antibodies against specific troponin degradation products 
or phosphorylated epitopes in order to provide a more comprehensive analysis of circulating 
troponins that might correlate with unique cardio pathophysiologies and emerge as a powerful 
diagnostic tool to guide clinical intervention.(31-35) 
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Figure 5.1 a) Layout of the microring arrays sensor chip indicating the position of antibodies 
spotted on microrings as well as thermal control rings and leak sensors. The chip is separated into 
two independent channels allowing analysis of two samples in parallel. b) Representative 
resonance shift from an enzymatically-enhanced sandwich assay detecting a 125 ng/ml ITC 
standard solution, starting from sample introduction at 3 min, addition of biotinylated tracer 
antibodies at 19 min, following by addition of SA-HRP at 24 min, and finally 1-step CN 
introduction at 29 min, with buffer rinse steps in between. 
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Figure 5.2 a) Instrumental response of various troponin ITC concentrations spiked in running 
buffer. The amplified signal upon addition of 1-step CN at 30 min can be clearly observed b) 
Corresponding calibration curve obtained based on fitting data points from net shift between 29-
40 min of the assay. Error bars were calculated based on the standard deviation of n=16 replicated 
microring measurements. 
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Figure 5.3 Calibration curve of troponin ITC concentrations spiked in 50% diluted serum. The 
inset graph illustrated serum matrix effects on the microring arrays assay, where a small amount 
of serum presented in the matrix can decrease the assay signal slightly. Error bars were calculated 
based on the standard deviation of n=16 replicated microring measurements. 
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Figure 5.4 a) Table listing cTnI concentrations (ng/ml) for serum samples from Patients A-K, 
measured by the microring arrays platform (n≥10 replicates) compared to the Siemens ADVIA 
Centaur XP-TnI platform (n=1). b) Plot of the cTnI levels of the patient samples measure by the 
Siemens platform (y-axis) versus the microring arrays platform (x-axis), suggesting a correlation 
between the measurements and a discrepancy in the troponin ITC standard used for calibration. 
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Figure 5.5 Correlation between troponin ITC standards concentration in 50% diluted serum and 
measured cTnI concentrations in the Siemens ADVIA Centaur XP-TnI platform. 
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Figure 5.6 a) Table listing cTnI concentrations (ng/ml) of 11 patients’ serum samples measured 
by the microring arrays platform (n≥10 replicates) after correction of troponin ITC standards 
concentration, and the respective comparison with measurements from the Siemens ADVIA 
Centaur XP-TnI platform (n=1 measurement). Also included is the percentage recovery of the 
patients’ samples measured on the microring array platform compared to the Siemens assay 
platform. b) Plot illustrating the linearity of cTnI concentrations measured on the microring arrays 
platform (x-axis) and the Siemens platform (y-axis). 
  
96 
 
 cTnI assay (running buffer) 
Signalmin 167 pm 
Signalmax 8537 pm 
Slope 0.931 
LOB 0.010 ng/ml  
LOD 0.015 ng/ml 
EC50 2.1 ng/ml 
Working range 0.5-9.4 ng/ml 
R2 0.995 
 
Table 5.1 Analytical metrics from buffer calibration curve (Figure 5.2). 
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 cTnI assay in 50% serum 
Signalmin 163 pm 
Signalmax 10338 pm 
Slope 0.608 
LOB 0.001 ng/ml 
LOD 0.003 ng/ml 
EC50 18.4 ng/ml 
Working range 1.9-178.5 ng/ml 
R2 0.999 
 
Table 5.2 Analytical metrics from serum calibration curve (Figure 5.3). 
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Chapter 6: 
Multiplex Monitoring of Immune System Biomarkers for 
Sepsis Diagnosis in a Hospital Intensive Care Unit 
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6.1 Abstract 
 A multiplexed assay was designed on a microring resonators platform for the detection of 
14 inflammatory biomarkers associated with sepsis. Assay performance for each biomarker was 
characterized to illustrate the capability of the assay to detect the markers at plasma-relevant 
concentrations. Potential interferences among biomarkers in the assay panel were identified, and 
matrix effects of human plasma on the assay platform were also evaluated. Lastly, plasma 
samples collected from a hospital patient during a time course of sepsis were analyzed on the 
multiplexed assay panel, and the results provided a glimpse of pro- and anti-inflammatory 
markers trajectory over the time course of a sepsis episode 
6.2 Introduction 
Sepsis is a life-threatening condition that is among the most common cause of death for 
patients in the intensive care units of the hospital, with the mortality rates in the same range as 
deaths caused by myocardial infarctions.(1) With the improvement of healthcare, the fatality due 
to sepsis has overall decreased, but since sepsis mostly target the elderly, the growing age of the 
population also leads to a growing number of sepsis cases and results in an overall increase in the 
total number of deaths.(2-4) Subsequently, there is a huge financial burden for sepsis treatment, 
and it is estimated that the USA dedicates $20 billion spending towards hospital care for sepsis 
during 2011.(5)  
Sepsis occurs due to host-response against systemic infection. In order to kill the 
invading pathogens, there is an acute release of multiple cell signaling molecules in the body to 
promote inflammation.(6) However, this high inflammatory response can lead to multiple organ 
failure that can be fatal. Currently, the criteria for sepsis diagnosis is based on monitoring 
clinical signs of systemic inflammatory response syndrome (SIRS), which is indicative of bodily 
trauma, and also in identifying the causative pathogen source that causes the infection.(7) For 
this latter point, the current gold standard for microbiological diagnosis is by using blood 
culture.(8) Unfortunately, there are limitations to this method, because the time required for 
blood culture is at 8-24 hours,(9) and upon a positive result in the culture, additional procedures 
such as gram-staining will be performed to further identify the pathogen.(10, 11) From a medical 
treatment standpoint, this long timeframe is undesirable, as physicians have to make immediate 
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treatment decisions before knowing the culture results, and consequently broad-spectrum 
antibiotics is liberally administered before clearly identifying the infectious pathogen source. 
Other than the long analysis time, there are additional drawbacks with this approach. Firstly, 
more than 50% of patients have negative blood culture results, despite their exhibition of sepsis-
related signs and symptoms.(12) Secondly, the antibiotics administered might turn out to be 
ineffective to kill off the pathogen type identified by the blood culture, and this in turn promotes 
the increasing problem of antimicrobial resistance for bacteria.(11, 13) 
At present, various molecular detection techniques are being investigated to improve 
upon the conventional blood culture method. Fluorescence in situ hybridization (FISH) is one 
such commercial method to identify the pathogen for a positive culture.(14, 15) Alternatively, 
DNA amplification strategies such has polymerase chain reaction (PCR) is also used.(16, 17) 
Another method that came up within the past 5-8 years is the use of mass spectrometry 
techniques to identify positive cultures.(18, 19) Nonetheless, these techniques do not work 
around the long timeframe required for blood cultures.(20) Thus, current research aims to 
perform analysis directly on the patient blood samples. The majority of direct blood sample 
analysis is based on DNA purification follow by multiplex PCR amplification strategies, yet 
preanalytical processing of the specimen is a big challenge since low levels of pathogens are 
found in blood,(21) and at present none of them are approved by the US Food and Drug 
Administration (FDA).(20) 
Other than detecting the microbiological source of infection, there is increasing interest in 
monitoring biomarkers as early indicator for sepsis or predictors of sepsis outcome. As 
mentioned earlier, sepsis stems from systemic inflammatory response to an infection, and its 
fatality is not solely due to the pathogen causing damage to tissues and cells, but more directly 
related to the triggered host immune response that causes widespread organ dysfunction.(22) It is 
established that the course of sepsis can be divided into two phases: pro-inflammatory phase and 
compensatory anti-inflammatory phase.(23) As its name implies, during the initial pro-
inflammatory phase large amounts of pro-inflammatory cytokines are released, and these 
cytokines are responsible for the hyper-inflammation that is characteristic of the initial phase of 
sepsis. Over time, if this condition is not resolved, this will progress to a compensatory phase 
where the immune system attempts to down-regulate the inflammation by producing anti-
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inflammatory cytokines. At this stage, the septic patient might still recover if appropriate 
measures are administered, but often this results in death. Currently, there are very few studies in 
the literature that look into how these pro- and anti-inflammatory markers variate over the 
duration of a sepsis episode and the associate patient prognosis, thus monitoring these markers 
trends can potentially correlate with sepsis prognosis patterns among different patients. 
Ultimately, this can help with earlier diagnosis of sepsis and improvement in how it can be 
treated. 
In this work, our goal is to develop an immunoassay panel for the multiplexed detection 
of 12 biomarkers based on sepsis literature. These biomarkers are: tumor necrosis factor-α (TNF-
α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), 
interleukin-18 (IL-18), interleukin-1 receptor antagonist (IL-1ra), monocyte chemotactic protein-
1 (MCP-1), procalcitonin (PCT), soluble tumor necrosis factor receptor-1 (sTNFRI), granulocyte 
colony-stimulating factor (G-CSF), and interferon-γ (IFN-γ). This panel consists of both pro-
inflammatory markers (TNF-α, IL-1β, and IL-6, IL-8, IL-18, MCP-1, IFN-γ) and anti-
inflammatory markers (sTNFRI, IL-1ra, IL-10), as well as other emergent markers that were 
reported to have correlation with sepsis in the literature.(24-29) 
In collaboration with Carle Foundation Hospital (Urbana, IL), blood plasma samples 
from patients suspected to suffer from sepsis were collected at multiple time points over their 
course of stay in the intensive care units (ICU) of the hospital. We then used our multiplexed 
panel to detect the levels of the 12 biomarkers over the entire duration of the patients’ stay in the 
ICU.  
At the time of publishing, this work is only partially completed. In this chapter, we 
present initial work demonstrating this 12-plex biomarker panel performance, as well as an 
evaluation of plasma samples from ten ICU patients. In the near future, we aim to broaden our 
test to evaluate more patients’ samples, as well as utilizing other physiological information 
collected about the patients for treatment purposes (E.g. Age, gender, body temperature, heart 
rate, blood count, blood pressure, medications, pre-existing conditions such family history etc.) 
to correlate our measured biomarker levels and the outcome of patients. 
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6.3 Materials and methods 
6.3.1 Patients selection and sample collection 
Patients recruited for the study were between 18-89 years of age, and admitted to the ICU 
of Carle Foundation Hospital in Urbana, IL with an admission diagnosis of sepsis. These patients 
were in poor state of health and required continuous monitoring and treatment, which included 
blood draws at regular time intervals for hospital laboratory tests. The blood samples were 
collected in lithium heparin-coated collection tubes to inhibit blood clotting, then centrifuged at 
4500 g (6 min, 4°C) to obtain blood plasma. Leftover plasma samples from hospital laboratory 
analysis were then stored at -80°C and sent to researchers at University of Illinois for the 12-plex 
biomarker panel analysis. 
6.3.2 Reagents and buffers 
 Zeba Spin desalting columns (Cat. 89882), EZ-link NHS-PEG4-Biotin (Cat.21329), 1-
step chloronaphthol solution (1-step CN, Cat. 34012), and high sensitivity streptavidin-
horseradish peroxidase conjugate (SA-HRP, Cat. 21130) were purchased from Thermo Fisher 
Scientific (Rockford, IL). Pooled normal human plasma (Cat. IPLA-N) was purchased from 
Innovative Research (Novi, MI). DryCoat assay stabilizer (Cat. AG066-1) and DryCoat assay 
stabilizer with blocking protein (Cat: AG044-1) were purchased from Virusys (Taneytown, MD). 
Recombinant biomarker antigen standards, capture and tracer antibodies used for the biomarker 
panel were obtained from various companies listed in Table 6.1. All remaining reagents not 
listed in this section were purchased from Sigma-Aldrich (St. Louis, MO). 
 10 mM phosphate buffer saline (PBS) solution was prepared by dissolving Dulbecco’s 
phosphate buffered saline powder to distilled water, filtered and adjusted to pH 7.4. Assay 
running buffer was prepared by dissolving 0.5% (w/v) bovine serum albumin (BSA) to 10 mM 
PBS. 
6.3.3 Biotinylation of tracer antibodies 
All of the tracer antibodies of the assay panel were purchased in biotinylated format, 
except for the tracer antibody for PCT, which was biotinylated in the laboratory. Procedures of 
biotinylation of this antibody was identical to that described in Chapter 5. Briefly, the antibody 
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was filtered through the desalting columns to remove excess sodium azide, and the antibody 
concentration was determined by NanoDrop spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE). Subsequently, 20 mM NHS-PEG4-Biotin was added to the antibody at 20× 
molar excess to incubate at room temperature for 30 min. The biotinylated antibody was then 
filtered through the desalting columns to 10 mM PBS storage solution, and the final 
concentration was measured by the NanoDrop spectrophotometer again. 
6.3.4 Capture antibodies immobilization on chips 
 In order to fit in a rather dense number of capture antibodies probes (12 biomarker 
antibodies  plus mouse IgG control spotted in duplicates, 26 probes to spot in total) on a small 
sensor chip footprint (4 mm × 6 mm), assay capture antibodies were sent to Genalyte (San Diego, 
CA) to be spotted on microring sensor arrays using a piezoelectric spotter. The immobilization 
chemistry is identical to the APTES/BS3 method described in Chapter 5 except for the final 
blocking step, where each spotted antibody probe was spotted over again with a layer of DryCoat 
with blocking protein solution to reduce non-specific interactions during the immunoassay run. 
6.3.5 Instrumentation 
 Microring resonator assay experiments were performed on the latest generation Maverick 
M24 instrument that was briefly mentioned in Chapter 1. Similar to the earlier Maverick M1 
generation instrument described extensively in Chapters 4 and 5, the M24 system also has an 
integrated assay fluidic system to automate assay reagents flow. The major innovation in the 
M24 design is that the microring array sensor chips come pre-assembled in a disposable cartridge 
of 12 chips. As shown in Figure. 6.1, this cartridge consists of inlet sipper tubes to draw assay 
samples/reagents pre-loaded in standard 96-well plates, as well as a fluidic gasket sealed over 
each individual chip. This fluidic gasket has cut-outs that align over the two sample channels of 
sensor microrings of each chip, allowing solutions drawn by the inlet tube to flow across the 
microrings, as well as outlet holes that can be connected to the waste lines of the instrument to 
discard used reagents. The design of this cartridge enables performing successive assay runs on 
all 12 chips in the array without pauses, which greatly facilitates testing of multiple clinical 
samples of patients at various sample collection time points required by this project. 
  
 107 
 
6.3.6 Microring resonator assay procedures 
 To perform microring resonator assays, a 96-well plate was first filled with assay 
reagents and samples/standards to be tested. This pre-filled well plate and the pre-assembled 
cartridge containing the antibody-spotted chips were then placed into the M24 instrument. A 
Maverick system control software was pre-programmed to control assay reagent delivery from 
the well plate to a single sensor chip in the cartridge, and two assays were performed 
simultaneously on this chip. After the assay runs on this chip were completed, the software 
automatically repeated the same procedures to the next chip in the cartridge. For each assay run, 
the total duration was 45.5 minutes. The assay was monitored in real-time in the following 
sequence: 1) assay running buffer rinse (3 min at 30 µl/min); 2) analyte standard/plasma sample 
(2 min at 40 µl/min, follow by 4.5 min at 20 µl/min); 3) assay buffer rinse (1 min, 40 µl/min); 4) 
biotinylated tracer antibodies cocktail (2 µg/ml for each antibody, 10 min at 30 µl/min); 5) assay 
buffer rinse (1 min at 40 µl/min); 6) SA-HRP (6 µg/ml, 10 min at 30 µl/min); 7) assay buffer 
rinse (2 min at 40 µl/min); 8) 1-step CN (9 min at 30 µl/min); 9) assay buffer rinse (3 min at 40 
µl/min). 
6.3.7 Data analysis 
 Data analysis was performed with OriginPro 2015 software. The net shift in resonance 
wavelength was determined by the difference in response between 34-45 min of the assay 
(before and after 1-step CN signal amplification step). Net shifts from analyte calibration 
standards were fit to the following dose response function: 
ݕ ൌ ܣ1 ൅ ܣ2 െ ܣ11 ൅ 10ሺ୪୭୥௫଴ି௫ሻ௣ 
where A1 is the bottom asymptote, A2 is the upper asymptote, x0 is the concentration at half 
response (EC50), and p is the hill slope of the fitted plot. In order to conform to guidelines for 
clinical diagnostic tests, the limit of blank (LOB) and limit of detection (LOD) were determined 
based on the EP17-A protocol published by Clinical and Laboratory Standards Institute 
(CLSI).(30, 31) Assuming a Gaussian distribution for instrumental response from blank samples, 
the LOB at 95th percentile of observed blank value is summarized as the following equation 
according to this protocol: 
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ܮܱܤ ൌ ݉݁ܽ݊௕௟௔௡௞ ൅ 1.645ሺܵܦ௕௟௔௡௞ሻ 
Where ݉݁ܽ݊௕௟௔௡௞ is the mean instrumental response from free of analyte sample measurements 
and ܵܦ௕௟௔௡௞ is the corresponding standard deviation of those measurements.  
For LOD determination, the equation is as follow: 
ܮܱܦ ൌ ܮܱܤ ൅ 1.645൫ܵܦ௟௢௪	௖௢௡௖௘௡௧௥௔௧௜௢௡	௦௔௠௣௟௘൯ 
Here, ܵܦ௟௢௪	௖௢௡௖௘௡௧௥௔௧௜௢௡	௦௔௠௣௟௘  refers to the standard deviation obtained from replicate 
measurements of a sample with known low analyte concentration. This sample selected should 
have an analyte concentration that generates an instrumental response between 1-4 times the 
response obtained from the LOB. 
Another point to note is that this protocol recommended clinical diagnostic tests 
manufacturers to obtain 60 replicate measurements to establish the LOB/LOD values for a 
diagnostic test platform, but at the time of publishing this chapter, these assay performance 
metrics were evaluated based on 12 replicate measurements per concentration from microring 
sensor arrays to obtain an estimate of the assays performance. In the future, these performance 
metrics will need to be more rigorously determined, especially when this project reaches the 
stage to draw any clinical diagnostics conclusions from patients’ samples. 
6.4 Results and discussion 
6.4.1 Dose-response calibration curves for 12-plex panel 
Each chip on the 12-chip disposable cartridge was spotted with antibodies in clusters of 
four microrings, as illustrated by the layout in Figure. 6.2a. It is worthwhile to note from this 
figure that the antibodies were spotted in identical positions on both channels for each individual 
chip, which enables two assay experiments to run simultaneously for the chip. The real-time 
instrument response from each assay run is illustrated in Figure. 6.2b, which showed each 
binding step of the assay run, from analyte standards delivery (t=3-9.5 min), biotinylated tracer 
antibodies (t=10.5-20.5 min), streptavidin-HRP (t=21.5-31.5 min), and the final precipitated 
enzymatic substrate upon 1-step CN delivery (t=33.5-42.5 min), with buffer rinses between each 
step.  
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In order to identify the working range of each assay for the 12 biomarkers in the sepsis 
marker panel, standard solutions were made as a cocktail of the 12 biomarker standards spiked 
into the assay running buffer to measure the instrumental response after 1-step CN delivery, and 
this response was fitted with dose-response fitting function to generate calibration curves. This 
experiment was repeated on three different days to determine the reproducibility of this 
multiplexed assay, and Figure 6.3 illustrated the results of the fitted curves after optimization. It 
was discovered that for markers IL-1ra and G-CSF, their range for plotting a dose-response 
calibration curve is from 6.4 pg/ml to 800000 pg/ml of spiked markers analyte. For markers 
MCP-1, PCT, sTNFRI, IL-1β, IL-6, IL-8, IL-10, and IL-18, their dose-response curves shift 
down to ranging from 1.2 pg/ml to 150000 pg/ml. For TNF-α and IFN-γ, the dose-response 
range shifts down to an even lower range between 0.24 pg/ml to 30000 pg/ml. Table 6.2 lists out 
the metrics of the fitted curves from each assay of the panel based on the average of all 
measurements on the three different days, while the LOB and LOD values were reported based 
on the average LOB and LOD obtained over the three different days.. As stated in the “Data 
Analysis” subsection, the reported LOB and LOD values are meant to be estimates for each of 
the biomarker assays, since they were only calculated from 12 replicate microring measurements 
over three different days. Commercial assays manufacturers often set a threshold to report “zero” 
effective concentration for scenarios where the actual blank measurement has a lower 
instrumental response than the blank response obtained by the fitted calibration function.(31) 
Nevertheless, it is expected that if more replicate measurements of blank and low concentration 
standards are taken, there will be a more accurate estimation of the assay LOB and LOD values 
in the future.  Another metric in Table 6.2 that puts some insight to the assay performance is the 
EC10 value reported for each assay. This value reports the concentration of the biomarker 
analyte that generates 10% of the maximum instrumental response for the assay. Overall, 
according to a literature report of evaluating the baseline concentration of 27 cytokines in healthy 
human subjects using a Luminex assay platform,(32) most of the biomarkers in the 12-plex 
microring arrays assay panel have comparable detection limits to detect baseline levels in healthy 
individuals. 
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6.4.2 Matrix effects of human plasma 
 After demonstrating assay quantitation for this 12-plex biomarker panel in assay running 
buffer, the next step in optimization is to apply this panel to evaluate biomarker levels in human 
plasma matrix. In our preliminary experiments, we spiked in saturating concentration of the 12 
biomarkers that were determined from our dose response curves (800 ng/ml for IL-1ra and G-
CSF, 30 ng/ml for TNF-α and IFN-γ, and 150 ng/ml for the remaining eight markers) to 0.5% 
BSA assay running buffer, 1:2 and 1:10 dilution of pooled healthy human plasma in assay 
running buffer. From the results illustrated in Figure. 6.4, most of the biomarkers showed 
equivalent response for the two plasma dilutions tested. Among the biomarkers that showed 
significant differences,  TNF-α and PCT showed ~2000 pm reduction in response, while sTNR1, 
IL-6, IL-10, and IL-18 showed a slight increase in response in diluted plasma matrix.  Non-
specific binding to mouse IgG negative control rings was drastically reduced when the assay was 
ran in diluted plasma matrix. The results from this matrix effects analysis also suggested that 
when testing human plasma samples for the majority of biomarkers in the panel (e.g. IL-1β, 
MCP-1, IL-1ra, IFN-γ, and IL-8), it is reasonable to perform assays at 1:10 sample dilutions, 
providing that the sample dilution does not decrease the biomarker level to lower than the assay 
detection limit. For the remaining markers, it might be necessary to correct for the matrix effects 
from plasma when determining the marker concentration in the sample. 
 In a separate experiment illustrated in Figure. 6.5, a pooled healthy human plasma sample 
was diluted to 1:10 plasma concentration and assayed on the 12-plex biomarker panel. From the 
figure, it is low levels of sTNFRI were detectable in this healthy pooled plasma sample. The 
concentration of sTNFRI in this pooled human plasma sample was determined to be ~155 pg/ml 
based on interpolation from the sTNFRI calibration curve in Figure 6.3. This result is 
unsurprising, since for healthy human plasma there is still a baseline level of immunoregulatory 
biomarkers. In the future, it is worthwhile to repeat this evaluation at higher pooled plasma 
concentration to determine if the baseline levels of other biomarkers are detectable. 
6.4.3 Plasma analysis from septic patients’ samples 
 After investigating the matrix effects of human plasma, we proceeded to evaluate the 
performance of the 12-plex biomarker assay panel on ten septic patients’ plasma samples. As 
shown in Figure 6.6, plasma samples were drawn from each patient at multiple time points 
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during his/her entire stay at the ICU of Carle Foundation Hospital. Each patient’s physiological 
and clinical conditions (e.g. Basal temperature, plasma pro-calcitonin levels, white blood cell 
counts etc.) and the time intervals between plasma collections were all recorded by the hospital 
staff, but this information was withheld from our personnel at the University of Illinois at this 
preliminary study stage. Thus, for the purpose of reporting our measurements from the 12-plex 
biomarker panel, the time points were denoted as arbitrary time point units as shown in Figure. 
6.6. The biomarker concentration for the evaluated time points for each patient was determined 
by interpolating the assay response to the calibration curves generated in Figure 6.3. Markers 
TNF-α, IL-1β, and IFN-γ had undetectable levels in all of the ten patients evaluated. Among the 
detectable markers PCT, sTNRI, and IL-6 levels mostly fall within the assay linear range for all 
the samples tested, and the interpolated concentrations are plotted in Figures 6.7-6.9. In general, 
PCT and IL-6 concentrations were the highest in the earlier time points and gradually decreased, 
and the IL-6 concentrations at certain time points for some patients were elevated beyond the 
linear range of the assay. In contrast, sTNFRI concentrations were rather consistently elevated 
over the assessed time points for all of the patients. Moreover, patients E, F, and G have lower 
concentrations of these three markers in comparison to the rest of the patients.  At present, it is 
unclear how the trajectory of each of these biomarker levels correlate with one another, but it is 
interesting to note that both pro-inflammatory (PCT, IL-6) and anti-inflammatory (sTNFRI) 
markers among some of the patients’ samples had elevated response on this 12-plex assay panel. 
Based on literature reports, pro-inflammatory markers are elevated initially in sepsis, and later on, 
anti-inflammatory markers levels will start increasing. It is speculated that some of these patients 
were admitted to the ICU after the pro-inflammatory phase of sepsis, thus high levels of anti-
inflammatory markers were also observed.  
6.5 Conclusions  
In conclusion, this initial work has demonstrated the multiplexed capability of the 
microring resonators platform to detect 12 different biomarkers associated with sepsis. 
Calibration standards in buffer solutions were tested across this multiplexed panel, and the 
results were fitted with dose-response functions to characterize the performance of each assay in 
the panel and to determine assay reproducibility. Potential matrix effects from human plasma 
was also studied. Finally, plasma samples from ten sepsis patient were analyzed by the microring 
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resonators platform, and the results indicated both the elevation of pro-inflammatory markers 
(PCT, IL-6) and anti-inflammatory markers (sTNFRI) markers during sepsis. Overall, these 
initial results showed great promise in using microring resonators for clinical analysis of sepsis 
biomarkers in hospital patients, which can provide further insights to the correlation between 
immunoregulatory biomarkers and sepsis prognosis.     
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Figure 6.1 Photograph of the chips cartridge for the Maverick M24 instrument. A total of 12 
sensor chips are placed into this cartridge, and each chip is connected to two inlet tubes that 
allow samples/assay reagents delivery to two channels with exposed microrings on the sensor 
chip surface. 
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Figure 6.2 a) Diagram of the sensor chip layout and the relative position of each antibody 
spotted on the chip surface. Mouse IgG antibodies do not have specific affinity for any antigens, 
thus serving as negative controls for the assays. Each antibody in the array is spotted over a 
cluster of four microrings, and repeated over the two fluidic channels of the chip. The rings in 
black represent temperature control rings, while the rings in white represent leak sensor rings, 
since that are normally occluded by the fluidic gaskets and left unexposed to reagent delivery 
through the channels. The arrows represent the flow direction of sample/reagents during an 
assays run. b) Representative sensogram data from an individual assay run of all 12 biomarkers 
spiked at high concentrations in assay running buffer. 
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Figure 6.4 Matrix effects of pooled human plasma. The 12 biomarkers standards were spiked at 
saturating concentrations. Error bars represent the standard deviation of n=4 replicated 
measurements. 
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Figure 6.5 Sensogram of an assay testing 1:10 dilution of pooled human plasma. From the 
sensogram, it is evident that low levels of sTNFRI are present in the pooled plasma sample. 
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Figure 6.6 Assay response of 1:10 dilution of plasma samples from ten patients (Patients A-J) 
across variable time points. Error bars represent standard deviation of n=4 replicated measured 
response. 
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Figure 6.7 Interpolated PCT concentrations of the plasma samples from all ten patients. Error 
bars represent the upper and lower concentration range based on the interpolated results 
accounting for the standard deviation in response in Figure 6.6. 
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Figure 6.8 Interpolated sTNFRI concentrations of the plasma samples from all ten patients. 
Error bars represent the upper and lower concentration range based on the interpolated results 
accounting for the standard deviation in response in Figure 6.6. 
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Figure 6.9 Interpolated IL-6 concentrations of the plasma samples from all ten patients. 
Columns shaded with diagonal lines indicate that the IL-6 levels exceeded the linear range of the 
calibration plot. Error bars represent the upper and lower concentration range based on the 
interpolated results accounting for the standard deviation in response in Figure 6.6. 
  
1 2 2  
Biomarker 
Antigen Standard 
Capture Antibody 
Tracer Antibody #1 
Tracer Antibody #2 
TNF‐α 
Biolegend 510102 
Biolegend 502802 
Biolegend 502904 
  
IL‐1β 
 eBioscience 14‐8018 
eBioscience 16‐7018‐85 
eBioscience 13‐7016‐85 
  
MCP‐1 
ebioscience 14‐8398‐80 
eBioscience 14‐7099‐85 
eBioscience 13‐7096‐85 
  
PCT 
Abbexa abx068668 
Abbexa abx019247 
Abbexa abx019248 
  
IL‐1ra 
Biolegend 714406 
R&D Systems MAB280 
R&D Systems BAF280 
Biolegend 509501 
sTNFRI 
R&D Systems 636‐R1‐025 
R&D Systems MAB625 
R&D Systems BAF225 
  
G‐CSF 
Biolegend 713402 
R&D Systems MAB214 
R&D Systems BAF214 
  
IFN‐γ 
Mabtech 3420‐10 
Mabtech 3420‐3‐250 
Mabtech 3420‐6‐250 
  
IL‐6 
eBioscience 14‐8069 
eBioscience 16‐7069 
eBioscience 13‐7068 
R&D Systems BAF206 
IL‐8 
R&D Systems 208‐IL 
BD Biosciences 554716 
BD Biosciences 554718 
R&D Systems BAF208 
IL‐10 
eBioscience 14‐8109‐80 
eBioscience 16‐7108‐85 
Biolegend 501501 
Invitrogen AHC7109 
IL‐18 
R&D Systems B001‐5 
R&D Systems D044‐3 
R&D Systems D045‐6 
  
 
Table 6.1. Catalogue numbers and vendors for all purchased antibodies and antigen standards used for the assay panel.
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Chapter 7: 
Future Directions 
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7.1 Introduction  
In this thesis, I have presented a summary of my research progress towards biomarker 
immunoassays development on a microring resonator platform, leading up to the translation of 
these assays to clinical diagnostic applications. The translational of immunoassays to clinical usage 
is an iterative process that involves trial and error of identifying correct biomarkers, assay 
development, clinical trials and outcome assessments. Particularly, the final two projects in this 
dissertation that involved collaboration with hospital physicians (Chapters 5 and 6) have excellent 
potential for more clinical studies with patients in the future.  
7.2 Future work of the troponin project 
For the cardiac troponins analysis project described in Chapter 5, future work can be 
expanded to multiplexed detection of other troponin degradation subunits/fragments in addition to 
cTnI. The troponin molecule consists of three subunits, out of which both the cTnI and cTnT 
subunits are highly specific to myocardial injury.(1) However at present stage, no troponin tests 
are available to simultaneously detect both the I and T subunits of a sample. Moreover, troponins 
released into circulation are subjected to degradation by serum proteases, and having the ability to 
detect and quantitate these fragmentation products are useful to understand cardiac dysfunction 
and disease prognosis.(2) Previously, we performed experiments on microring arrays platform that 
demonstrated the ability to distinguish between cTnI and cTnT subunits (Fig. 7.1). In the future, 
we can expand upon this work to detect other troponin fragments through a careful design of 
capture and tracer antibodies used in assays. 
Another future direction for the troponin project is in the detection of troponin 
autoantibodies. Troponin autoantibodies are known to be found in both healthy individuals or 
patients afflicted with heart diseases, and currently troponin autoimmunity is not well 
understood.(3) However, it is reported that these autoantibodies can interfere with antibodies that 
are used in immunoassays, thus leading to false negative results.(4) One possible way to utilize 
microring resonators for troponin autoantibodies detection is through the use of peptide arrays. As 
a proof-of-principle experiment, peptide sequences that correspond to epitopes targeted by anti-
cTnI assay antibodies are immobilized on different microring clusters of a sensor chip. Each 
individual anti-cTnI antibody is then sequentially flowed across the peptide-immobilized ring 
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clusters. As illustrated in Figure. 7.2, the antibodies are only specific to the peptides that 
correspond to their respective targeted epitopes and do not cross-react with the mismatched peptide 
sequences. Thus, this peptide array can potentially be used for detecting troponin autoantibodies 
that have similar epitope targets. 
7.3 Future work of sepsis biomarker panel project 
The sepsis biomarkers panel project described in the previous Chapter 6 has great promise 
of applying to clinical settings for monitoring sepsis progression in patients. In the short term, 
dilution of plasma samples should be investigated to optimize the measured response within the 
linear range of the assays for determining the concentration of each marker. As the project achieves 
quantitative detection of the 12 biomarkers in the panel, more septic patients’ samples should be 
analyzed, and at this stage the results of the measurements should be validated by an external 
established method, such as ELISAs or the Luminex™ assay platform. This will give a good 
assessment of the microring resonator platform’s performance in quantitation of sepsis markers. 
With the biomarker concentrations in the patients’ plasma samples determined, these results can 
be used along other physiological information collected by the treating physicians to correlate the 
measured biomarker levels with patients’ outcomes, and hopefully this information can aid in 
improving treatment of sepsis. 
Finally, it should be recognized that as a hallmark of translational study, various steps in 
this project, beginning from biomarker screening, assay optimization, clinical trials, to correlation 
of results to disease prognosis of the patient, all require cooperative efforts between physicians, 
laboratory technicians, as well as data scientists, and this collaboration should continue on in the 
future to have successful achievements. 
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Figure 7.1 Sequential delivery of tracer antibodies specific against cTnI and cTnT demonstrates 
the ability to differentiate between troponin ITC complex and the cTnI subunit. 
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Figure 7.2 a) Schematic of the entire cTnI amino acid sequence, highlighting specific epitopes 
(residues 23-29, 41-49, and 190-196) that are targeted by anti-cTnI antibody clones 4C2, 19C7, 
and MF4. b) Schematic illustration of microring resonator arrays presenting the three selected 
peptide epitopes in a). c) Real-time microring resonator responses the three selected antibodies 
binding to their corresponding targeted peptide epitopes. Each columns represent the simultaneous 
probing of the three selected peptide sequences with a single antibody clone. From the figure, the 
antibody-peptide binding response are highly specific with minimal cross-reactivity observable. 
Thus, the same peptide array principle can potentially be applied to detecting autoantibodies that 
interfere with cTnI assays. 
 
  
b) 
a)  c) 
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